Indole and benzimidazole compounds as factor b inhibitors

Abstract

The present invention relates to compounds possessing an indole or benzimidazole moiety linked to a cyclic group via an amide bond, to compounds having similar core structures, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.

Description

[0001] INDOLE AND BENZIMIDAZOLE COMPOUNDS AS FACTOR B INHIBITORS

[0002] Field of the Invention

[0003] The present invention relates to compounds possessing an indole or benzimidazole moiety linked to a cyclic group via an amide bond, to compounds having similar core structures, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.

[0004] Background of the Invention

[0005] The complement system is a critical part of the innate immune system and serves to help the body fight against infection from pathogens, ultimately leading to inflammation and phagocytic removal of pathogens or foreign particles.

[0006] The complement system is comprised of multiple proteins, including zymogens which undergo proteolytic cleavage to become activated and facilitate the activation of further zymogens in the cascade. The proteins may be zymogens or proteins without potential for enzymatic activity that change conformation revealing binding sites for other components of the system. These successive enzymatic cleavages lead to a large, amplified response and many regulatory components exist in this system to prevent uncontrolled activation.

[0007] The complement system can be activated via three pathways: classical, lectin, and alternative. The classical pathway is triggered by antigen :antibody complexes and connects the innate to the adaptive immune system. The lectin pathway is triggered directly by the pathogen when serum protein mannan-binding lectin, collectins or ficolins bind to bacterial or viral mannose-containing carbohydrates. The alternative pathway (also known as the alternate pathway) is initiated by activation of the central complement component, C3, either through spontaneous hydrolysis or enzymatic cleavage. The alternative pathway also serves as a critical amplification loop of all three pathways of complement activation.

[0008] Ultimately, all of these pathways lead to the generation of C3 convertase which cleaves and activates further C3 molecules to promote: 1) opsonization of pathogens so they can be engulfed by phagocytes that recognise key receptors, 2) the recruitment of inflammatory cells by generating chemoattractants at the site of activation, and 3) formation of the C5 convertase resulting in production of C5a and C5b, the latter of which induces direct killing of pathogens by assembling terminal complement components to create membrane attack complex (MAC) pores in the membrane of bacteria or other target cells (Janeway, C. A. Jr. et al, (2001) The complement system and innate immunity, in Immunobiology: The Immune System in Health and Disease, Garland Science, New York).

[0009] Factor B, a trypsin-like serine protease, is an element of the alternative pathway of the complement cascade. It exists in circulation in its zymogen form until the pathway becomes activated (Schubart, A. et al, Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 7926-7931).

[0010] Spontaneous steady-state hydrolysis of C3 leads to the formation of C3(H2O). Factor B can bind to the active forms of C3: C3(H2O) and C3b, generating the proenzyme C3bB (or C3(H2O)B), a target for activation by Factor D. Upon cleavage by Factor D, two fragments are generated: Ba and Bb (Schwaeble, W. J., Ali, Y. M., and Sim, R. B., (2020) Chapter 14 - The Roles and Contributions of the Complement System in the Pathophysiology of Autoimmune Diseases, in The Autoimmune Diseases (Sixth Edition) (Rose, N. R., and Mackay, I. R. eds.), Academic Press). Ba is released and Bb, containing a serine protease domain, remains bound to C3(H2O) and C3b, forming the alternative pathway C3 convertases [C3(H2O)Bb and C3bBb]. These trigger the amplification loop by converting C3 to C3a and more C3b. With the addition of yet another C3b to the C3 convertase, the C5 convertase is generated (C3bBbC3b) (Laskowski, J., Thurman, J. M. (2018) Chapter 14 - Factor B, in The Complement FactsBook (Second Edition) (Barnum, S., and Schein, T. eds.), Academic Press). C5 convertase cleaves C5 to generate the anaphylatoxin C5a, and C5b which serves as a platform for the formation of the membrane attack complex.

[0011] Dysregulation of the alternative complement pathway due to genetics or the presence of autoantibodies can lead to many different diseases. Inhibition of Factor B is therefore a key therapeutic target for modulation of the alternative pathway and hence the treatment of numerous diseases, disorders and conditions.

[0012] Iptacopan (LNP023), disclosed in Mainolfi et al., J. Med. Chem., 2020, vol. 63, pp. 5697-5722, is a known Factor B inhibitor having the following structure:

[0013] Iptacopan is highly selective for Factor B, showing no inhibition of Factor D or the classical or lectin complement pathways. Also, no significant effects have been observed in a broad assay panel of receptors, ion channels, kinases, and proteases (Schubart, A. et al, Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 7926-7931). The drug has recently undergone successful phase III clinical studies in patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) (Novartis Press Release, "Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naive PNH patients", 26 April 2023).

[0014] Further indole derivatives stated to have Factor B inhibitory activity are disclosed in WO 2013 / 164802 Al, US 2013 / 0296377 Al, WO 2014 / 143638 Al, WO 2015 / 009616 Al, WO 2022 / 028507 Al, WO 2022 / 028527 Al, WO 2022 / 143940 Al, WO 2022 / 143845 Al, WO 2022 / 155294 Al, WO 2022 / 218429 Al, WO 2022 / 256586 A2, WO 2023 / 278698 Al, WO 2023 / 020566 Al, WO 2023 / 072197 Al, WO 2023 / 139534 Al, WO 2023 / 187715 Al, WO 2024 / 049977 Al, WO 2025 / 008451 Al, WO 2025 / 008453 Al, WO 2025 / 008516 A2 and WO 2025 / 008517 Al.

[0015] However, there is a need to provide further Factor B inhibitors, especially selective Factor B inhibitors (e.g. versus inhibition of Factor D, classical complement, and / or lectin complement activation). In particular, there is a need to provide compounds with improved pharmacological and / or physiological and / or physicochemical properties and / or those that provide a useful alternative to known compounds.

[0016] Summary of the Invention

[0017] A first aspect of the invention provides a compound of Formula (I): wherein :

[0018] R1is hydrogen;

[0019] R2is selected from hydrogen or a halo, -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0020] Q3is selected from N or C-R3;

[0021] R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0022] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0023] R5is selected from hydrogen or a halo group;

[0024] R6is selected from a halo, -R60or -OR60group, wherein R60is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group;

[0025] R7and R8are each independently selected from hydrogen or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; or R3and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom;

[0026] R9is hydrogen;

[0027] L is selected from a bond, -O-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; and

[0028] R10is a 3- to 12-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety.

[0029] In one embodiment of the first aspect of the invention, Q3is C-R3, i.e. the compound has the Formula (la):

[0030]

[0031] Formula (la) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10and L are as defined in accordance with Formula (I).

[0032] Typically in such an embodiment:

[0033] R2is selected from hydrogen or a halo group;

[0034] R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0035] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0036] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group; R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; or R3and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0037] In another embodiment of the first aspect of the invention, Q3is N, i.e. the compound has the Formula (lb):

[0038]

[0039] Formula (lb) wherein R1, R2, R4, R5, R6, R7, R8, R9, R10and L are as defined in accordance with Formula (I).

[0040] A second aspect of the invention provides a compound of Formula (II) :

[0041] Formula (II) wherein :

[0042] R1is hydrogen;

[0043] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0044] R5is selected from hydrogen or a halo group;

[0045] R6is selected from a halo, -R60or -OR60group, wherein R60is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group;

[0046] R7and R8are each independently selected from hydrogen or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton;

[0047] R9is hydrogen;

[0048] R14is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group; and

[0049] R15is selected from hydrogen or a -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;

[0050] R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0051] R17is selected from hydrogen or a fluoro, C1-C4 alkyl, cyclopropylmethyl, C3- C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted; or R17and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom;

[0052] L is selected from a bond, -0-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; and

[0053] R10is a 3- to 12-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety.

[0054] In one embodiment of the second aspect of the invention :

[0055] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0056] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0057] R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; each R14and R15is independently selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;

[0058] R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0059] R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted; or R17and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0060] In the context of the present specification, a "hydrocarbyl" substituent group or a hydrocarbyl moiety in a substituent group only includes carbon and hydrogen atoms but, unless stated otherwise, does not include any heteroatoms, such as N, O or S, in its carbon skeleton. A hydrocarbyl group / moiety may be saturated or unsaturated (including aromatic), and may be straight-chained or branched, or be or include cyclic groups wherein, unless stated otherwise, the cyclic group does not include any heteroatoms, such as N, O or S, in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and aryl groups / moieties and combinations of all of these groups / moieties. Typically a hydrocarbyl group is a C1-C20 hydrocarbyl group. More typically a hydrocarbyl group is a C1-C15 hydrocarbyl group. More typically a hydrocarbyl group is a C1-C10 hydrocarbyl group. A "hydrocarbylene" group is similarly defined as a divalent hydrocarbyl group.

[0061] As used herein, the "chain length" of a hydrocarbylene group refers to the number of atoms of the hydrocarbylene group that are bonded to each other in a continuous chain between the two points of attachment of the hydrocarbylene group to the remainder of the molecule, as measured by the shortest route. By way of example, structure (C) has a chain length between A and B of 3 atoms, whereas structure (D) has a chain length between A and B of 5 atoms: An "alkyl" substituent group or an alkyl moiety in a substituent group may be linear (i.e. straight-chained) or branched. Examples of alkyl groups / moieties include methyl, ethyl, n-propyl, / -propyl, n-butyl, / -butyl, t-butyl and n-pentyl groups / moieties. Unless stated otherwise, the term "alkyl" does not include "cycloalkyl". Typically an alkyl group is a C1-C12 alkyl group. More typically an alkyl group is a Ci-Ce alkyl group. An "alkylene" group is similarly defined as a divalent alkyl group.

[0062] An "alkenyl" substituent group or an alkenyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds. Examples of alkenyl groups / moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl and 1,4-hexadienyl groups / moieties. Unless stated otherwise, the term "alkenyl" does not include "cycloalkenyl". Typically an alkenyl group is a C2-C12 alkenyl group. More typically an alkenyl group is a C2-C6 alkenyl group. An "alkenylene" group is similarly defined as a divalent alkenyl group.

[0063] An "alkynyl" substituent group or an alkynyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups / moieties include ethynyl, propargyl, but-l-ynyl and but-2-ynyl groups / moieties. Typically an alkynyl group is a C2-C12 alkynyl group. More typically an alkynyl group is a C2-C6 alkynyl group. An "alkynylene" group is similarly defined as a divalent alkynyl group.

[0064] A "cyclic" substituent group or a cyclic moiety in a substituent group refers to any hydrocarbyl ring, wherein the hydrocarbyl ring may be saturated or unsaturated (including aromatic) and may include one or more heteroatoms, e.g. N, O or S, in its carbon skeleton. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl groups as discussed below. A cyclic group may be monocyclic, bicyclic (e.g. bridged, fused or spiro), or polycyclic. Typically, a cyclic group is a 3- to 12-membered cyclic group, which means it contains from 3 to 12 ring atoms. More typically, a cyclic group is a 3- to 7-membered monocyclic group, which means it contains from 3 to 7 ring atoms.

[0065] For the avoidance of doubt, where it is stated that a bicyclic or polycyclic group or moiety is "saturated" it is to be understood that all of the ring systems within the bicyclic or polycyclic group or moiety (excluding any ring systems which are part of or formed by optional substituents) are saturated.

[0066] A "heterocyclic" substituent group or a heterocyclic moiety in a substituent group refers to a cyclic group or moiety including one or more carbon atoms and one or more (such as one, two, three or four) heteroatoms, e.g. N, O or S, in the ring structure. Examples of heterocyclic groups include heteroaryl groups as discussed below and non-aromatic heterocyclic groups such as azetinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, dioxanyl, morpholinyl and thiomorpholinyl groups.

[0067] A "cycloalkyl" substituent group or a cycloalkyl moiety in a substituent group refers to a saturated hydrocarbyl ring containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Unless stated otherwise, a cycloalkyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings.

[0068] A "cycloalkenyl" substituent group or a cycloalkenyl moiety in a substituent group refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carboncarbon double bonds and containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopent-l-en-l-yl, cyclohex-l-en-l-yl and cyclohex- 1,3-dien-l-yl. Unless stated otherwise, a cycloalkenyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings.

[0069] An "aryl" substituent group or an aryl moiety in a substituent group refers to an aromatic hydrocarbyl ring. The term "aryl" refers to monocyclic aromatic hydrocarbons and polycyclic fused ring aromatic hydrocarbons wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of aryl groups / moieties include phenyl, naphthyl, anthracenyl and phenanthrenyl. Unless stated otherwise, the term "aryl" does not include "heteroaryl".

[0070] A "heteroaryl" substituent group or a heteroaryl moiety in a substituent group refers to an aromatic heterocyclic group or moiety. The term "heteroaryl" refers to monocyclic aromatic heterocycles and polycyclic fused ring aromatic heterocycles wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of heteroaryl groups / moieties include the following: wherein G = O, S or NH. Particular examples of 5- or 6-membered heteroaryl groups include furanyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, furazanyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl groups.

[0071] Unless stated otherwise, where a bicyclic or polycyclic group or moiety is stated to be aromatic, such as an aryl or a heteroaryl group, it is to be understood that all of the ring systems within the bicyclic or polycyclic group or moiety (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Similarly, where a bicyclic or polycyclic group or moiety is stated to be nonaromatic, such as a cycloalkyl, cycloalkenyl or non-aromatic heterocyclic group, it is to be understood that all of the ring systems within the bicyclic or polycyclic group or moiety (excluding any ring systems which are part of or formed by optional substituents) are non-aromatic.

[0072] For the purposes of the present specification, where a combination of moieties is referred to as one group, for example, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl, the last mentioned moiety contains the atom by which the group is attached to the rest of the molecule. An example of an arylalkyl group is benzyl.

[0073] As will be appreciated, in an optionally substituted moiety: each hydrogen atom may optionally be replaced by any specified monovalent substituent; any two hydrogen atoms attached to the same carbon or nitrogen atom may optionally be replaced by any specified n-bonded substituent; any sulphur atom may optionally be substituted with one or two of any specified n-bonded substituents; and any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by any specified divalent bridging substituent.

[0074] Typically a substituted group comprises 1, 2, 3 or 4 substituents, more typically 1, 2 or 3 substituents, more typically 1 or 2 substituents, and more typically 1 substituent.

[0075] Unless stated otherwise, any divalent bridging substituent (e.g. -O-, -S-, -NH-, -CH2-, -CH2-CH2-, etc.) of an optionally substituted group or moiety (e.g. R1) must only be attached to the specified group or moiety and may not be attached to a second group or moiety (e.g. R2), even if the second group or moiety can itself be optionally substituted.

[0076] The term "halo" includes fluoro, chloro, bromo and iodo.

[0077] Unless stated otherwise, where a group is prefixed by the term "halo", such as a haloalkyl or halomethyl group, it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution on the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four or five halo substituents. Similarly, unless stated otherwise, where a group is prefixed by a specific halo group, it is to be understood that the group in question is substituted with one or more of the specific halo groups. For example, the term "fluoromethyl" refers to a methyl group substituted with one, two or three fluoro groups.

[0078] Similarly, unless stated otherwise, where a group is said to be "halo-substituted", it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution on the group said to be halo-substituted. For example, a halo-substituted methyl group may contain one, two or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four or five halo substituents.

[0079] Unless stated otherwise, any reference to an element is to be considered a reference to all isotopes of that element. Thus, for example, unless stated otherwise any reference to hydrogen is considered to encompass all isotopes of hydrogen including deuterium and tritium.

[0080] Unless stated otherwise, any reference to a compound or group is to be considered a reference to all tautomers of that compound or group.

[0081] Where reference is made to a hydrocarbyl or other group including one or more heteroatoms N, O or S in its carbon skeleton, or where reference is made to a carbon atom of a hydrocarbyl or other group being replaced by an N, O or S atom, what is intended is that:

[0082] I L

[0083] - C - - N -

[0084] I is replaced by I ;

[0085] —CH— — N—

[0086] | is replaced by |

[0087] -CH2- is replaced by -NH-, -O- or -S-;

[0088] -CH3 is replaced by -NH2, -OH or -SH;

[0089] -CH= is replaced by -N = ;

[0090] CH2= is replaced by NH = , 0= or S = ; or

[0091] CH= is replaced by N = ; provided that the resultant group comprises at least one carbon atom. For example, methoxy, dimethylamino and aminoethyl groups are considered to be hydrocarbyl groups including one or more heteroatoms N, O or S in their carbon skeleton.

[0092] Typically, the compounds of the invention contain no more than one quaternary ammonium group. More typically, the compounds of the invention contain no quaternary ammonium groups.

[0093] In the context of the present specification, unless otherwise stated, a Cx-Cygroup is defined as a group containing from x to y carbon atoms. For example, a C1-C4 alkyl group is defined as an alkyl group containing from 1 to 4 carbon atoms. For the purposes of allocating x and y in a Cx-Cygroup, optional substituents are not taken into account when calculating the total number of carbon atoms in the parent group substituted with the optional substituents. For the avoidance of doubt, replacement heteroatoms, e.g. N, O or S, are not to be counted as carbon atoms when calculating the number of carbon atoms in a Cx-Cygroup. For example, a morpholinyl group is to be considered a C4 heterocyclic group, not a Ce heterocyclic group.

[0094] For the purposes of the present specification, where it is stated that a first atom or group is "directly attached" to a second atom or group it is to be understood that the first atom or group is covalently bonded to the second atom or group with no intervening atom(s) or group(s) being present. So, for example, for the group -(C=O)N(CH3)2, the carbon atom of each methyl group is directly attached to the nitrogen atom and the carbon atom of the carbonyl group is directly attached to the nitrogen atom, but the carbon atom of the carbonyl group is not directly attached to the carbon atom of either methyl group.

[0095] As stated in accordance with the first aspect of the invention, R2is selected from hydrogen or a halo (e.g. fluoro, chloro or bromo), -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety.

[0096] In one aspect of such an embodiment, R2is selected from hydrogen or a halo group. For example, R2may be selected from hydrogen or a fluoro, chloro or bromo group. Typically in such an aspect, Q3is C-R3.

[0097] In another aspect of such an embodiment, R2is selected from hydrogen or a fluoro or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety.

[0098] In yet another aspect of such an embodiment, R2is selected from hydrogen or a Ci- Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo ( = 0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N and O in its carbon skeleton.

[0099] In a further aspect of such an embodiment, R2is selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, cyclopropylmethyl, C1-C4 fluoroalkyl, C3-C4 fluorocycloalkyl or fluorocyclopropylmethyl group. Typically in such an embodiment, R2is selected from hydrogen or a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. More typically, R2is selected from hydrogen or a methyl or fluoromethyl group.

[0100] Most typically, R2is hydrogen.

[0101] As stated in accordance with the first aspect of the invention, R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, or R3and R7together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0102] In one embodiment, R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety.

[0103] In one aspect of such an embodiment, R3is selected from hydrogen or a halo (e.g. fluoro, chloro or bromo), -R30, -CH2R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a Ci-Ce alkyl, Ci-Ce fluoroalkyl, C2-C6 alkenyl, C2-C6 fluoroalkenyl or -R31group, wherein R31is a 3- to 6-membered monocyclic group, wherein the 3- to 6-membered monocyclic group may optionally be substituted with one or more halo (e.g. fluoro, chloro or bromo) groups, and / or with one or two groups R32, wherein each R32is independently selected from a methyl or a fluoromethyl group, provided that the group R3, including any optional substituents, contains no more than 8 carbon atoms. Typically in such an embodiment, R3is selected from hydrogen or a fluoro, chloro, bromo, -R30, -CH2R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a C1-C4 alkyl, C1-C4 fluoroalkyl or -R31group, wherein R31is selected from a C3-C6 cycloalkyl group, a 4- to 6-membered saturated heterocyclic group, or a phenyl or a 5- or 6- membered heteroaryl group, wherein the C3-C6 cycloalkyl group and the 4- to 6- membered saturated heterocyclic group may optionally be substituted with one or more fluoro groups and / or with one or two groups R32, and wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two groups R32, provided that the group R3, including any optional substituents, contains no more than 8 carbon atoms. More typically in such an embodiment, R3is selected from hydrogen or a fluoro, chloro, bromo, -R30, -R31, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a methyl or fluoromethyl group, and wherein R31is a 5-membered heteroaryl group, wherein the 5-membered heteroaryl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two groups R32.

[0104] In another aspect of such an embodiment, R3is selected from hydrogen or a halo (e.g. fluoro, chloro or bromo), -R30, -CH2R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. Typically in such an aspect, R3is selected from hydrogen or a halo (e.g. fluoro, chloro or bromo), -R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group. More typically in such an aspect, R3is selected from hydrogen or a fluoro, chloro, bromo -R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a methyl or fluoromethyl group.

[0105] In a further aspect of such an embodiment, R3is selected from hydrogen or a halo (e.g. fluoro, chloro or bromo), -CN, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group. Typically in such an aspect, R3is selected from hydrogen or a halo (e.g. fluoro, chloro or bromo), -CN, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. More typically still in such an aspect, R3is selected from hydrogen or a fluoro, chloro, bromo, -CN or methyl group, wherein the methyl group may optionally be fluoro substituted.

[0106] More typically, R3is selected from hydrogen or a fluoro, chloro or bromo group. Most typically, R3is hydrogen.

[0107] In another embodiment of the first aspect of the invention, R3and R7together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom. Typically, where R3and R7together form a hydrocarbylene group, the hydrocarbylene group, including any optional substituents, contains no more than four carbon atoms.

[0108] Typically, the total number of nitrogen, oxygen and sulphur atoms in any hydrocarbylene group (including any optional substituents) formed by R3and R7is no more than three. More typically, the total number of nitrogen, oxygen and sulphur atoms in any hydrocarbylene group (including any optional substituents) formed by R3and R7is no more than two.

[0109] Typically in such an embodiment, R3and R7together form a C1-C4 saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbylene group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and wherein the hydrocarbylene group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0110] Where R3and R7together form a hydrocarbylene group, typically the hydrocarbylene group has a chain length of from 1 to 3 atoms. More typically, the hydrocarbylene group has a chain length of 1 or 2 atoms.

[0111] More typically, where R3and R7together form a hydrocarbylene group, the hydrocarbylene group is selected from -CH2-, -CH2-CH2-, -CH=CH-, -CH2-O-, or -O-CH2-, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0112] Typically, where R3and R7together form a hydrocarbylene group, R8is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. More typically, where R3and R7together form a hydrocarbylene group, R8is selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. More typically still, where R3and R7together form a hydrocarbylene group, R8is selected from hydrogen or a methyl or fluoromethyl group. Yet more typically, where R3and R7together form a hydrocarbylene group, R8is hydrogen. As stated in accordance with both the first and the second aspects of the invention, R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, or R4and R7together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0113] In one embodiment, R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety.

[0114] Typically in such an embodiment, R4is selected from hydrogen or a fluoro, chloro, bromo, -OH, -NH2, -SO2NH2, -SO2-R40or -R40group, wherein R40is selected from a Ci-Ce saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and wherein the hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N and O in its carbon skeleton.

[0115] More typically in such an embodiment, R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)2, -SO2-R41, -SO2-N(R42)2, -L4-OH, -L4-OR41, -L4-N(R42)2, -L4-SO2-R41, -L4-SO2-N(R42)2, -O-L4-OH, -O-L4-OR41, -O-L4-N(R42)2, -O-L4-SO2-R41, -O-L4-SO2-N(R42)2, -NR43-L4-OH, -NR43-L4-OR41, -NR43-L4-N(R42)2, -NR43-L4-SO2-R41, -NR43-L4-SO2-N(R42)2, -SO2-L4-OH, -SO2-L4-OR41, -SO2-L4-N(R42)2, -R44, -R45or -L4-R45group, wherein :

[0116] R41is selected from a -R44or -R45group; each R42is independently selected from hydrogen or a -R44or -R45group, or any two R42may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0117] L4is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L4has a chain length of from 1 to 4 atoms, and wherein L4may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL4; each RL4is independently selected from a fluoro, methyl or fluoromethyl group; or any RL4and R41, or any RL4and any R42, may together with the atoms to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0118] R43is selected from hydrogen or a -R44group; each R44is independently selected from a C1-C4 alkyl, C3-C6 cycloalkyl or C4- Ce cycloalkylalkyl group, wherein the C1-C4 alkyl, C3-C6 cycloalkyl or C4-C6 cycloalkylalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and each R45is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe?, wherein any methyl group of R45may optionally be fluoro substituted; provided that R4, including any optional substituents, contains no more than 8 carbon atoms.

[0119] In one aspect of such an embodiment, R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)2, -SO2-R41, -SO2-N(R42)2, -L4-OH, -L4-OR41, -L4-N(R42)2, -L4-SO2-R41, -L4-SO2-N(R42)2, -O-L4-OH, -O-L4-OR41, -O-L4-N(R42)2, -O-L4-SO2-R41, -O-L4-SO2-N(R42)2, -NR43-L4-OH, -NR43-L4-OR41, -NR43-L4-N(R42)2, -NR43-L4-SO2-R41, -NR43-L4-SO2-N(R42)2, -R44, -R45or -L4-R45group;

[0120] R41is selected from a -R44or -R45group; each R42is independently selected from hydrogen or a -R44or -R45group, or any two R42may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and each RL4is independently selected from a fluoro, methyl or fluoromethyl group; or any RL4and R41, or any RL4and any R42, may together with the atoms to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and each R44is independently selected from a C1-C4 alkyl or C3-C6 cycloalkyl group, wherein the C1-C4 alkyl or C3-C6 cycloalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups.

[0121] Typically, R4, including any optional substituents, contains no more than 6 carbon atoms.

[0122] Typically, the total number of nitrogen, oxygen and sulphur atoms in R4, including any optional substituents, is no more than four. More typically, the total number of nitrogen, oxygen and sulphur atoms in R4, including any optional substituents, is no more than three.

[0123] In one aspect of such an embodiment, R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)2, -SO2-R41, -SO2-N(R42)2, -R44or -R45group. In a more typical embodiment, R4is selected from a fluoro, chloro, bromo, -OH, -OR44, -N(R42)2, -COOH, -COOR44, -CON(R42)2, -SO2-R44, -SO2-N(R42)2, -O-L4-OH, -O-L4-OR44, -O-L4-N(R42)2, -NR43-L4-OH, -NR43-L4-OR44, -NR43-L4-N(R42)2, or -R44group, wherein : each R42is independently selected from hydrogen or a -R44group;

[0124] R43is selected from hydrogen or a -R44group; each R44is independently selected from a C1-C4 alkyl, C3-C6 cycloalkyl or C4- Ce cycloalkylalkyl group, wherein the C1-C4 alkyl, C3-C6 cycloalkyl or C4-C6 cycloalkylalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and

[0125] L4is a -CH2-CH2-, -CH2-CHMe-, -CH2-CMe2-, -CHMe-CH2-, -CHMe-CHMe-, -CHMe-CMe2-, -CMe2-CH2-, -CMe2-CHMe- or -CMe2-CMe2- group, wherein any -CH2-, -CHMe- or -CMe2- group may optionally be fluoro substituted.

[0126] Typically in such an embodiment, R4is selected from a fluoro, chloro, bromo, -OR44, -CON(R42)2, -SO2-R44, -SO2-N(R42)2, -O-CH2-CH2-OR44, -O-CH2-CH2-N(R42)2, or -R44group. More typically in such an embodiment, R4is selected from a fluoro, chloro, bromo, -OR44, -CON(R42)2, -SO2-R44, -O-CH2-CH2-OR44, -O-CH2-CH2-N(R42)2, or -R44group.

[0127] In one embodiment, each R44is independently selected from a C1-C4 alkyl, cyclopropylmethyl or C3-C6 cycloalkyl group, wherein the C1-C4 alkyl, cyclopropylmethyl or C3-C6 cycloalkyl group may optionally be substituted with one or more fluoro groups. More typically, each R44is independently selected from a Ci- C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group.

[0128] In a further embodiment, R4is selected from a fluoro, chloro, bromo, -OR44, -SO2-R44, -SO2-N(R42)2, -O-CH2-CH2-N(R42)2, or -R44group. More typically, R4is selected from a fluoro, chloro, bromo, -R44, -OR44or -SO2-R44group. More typically still, R4is selected from a -R44, -OR44or -SO2-R44group. Typically in such embodiments, R44is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group.

[0129] Yet more typically, R4is selected from a fluoro, chloro, bromo, methyl (Me), -OMe or -SChMe group, wherein any methyl group may optionally be fluoro substituted. More typically still, R4is selected from a methyl (Me), -OMe or -SO2Me group, wherein any methyl group may optionally be fluoro substituted. Most typically, R4is selected from a -OMe or -SChMe group, wherein any methyl group may optionally be fluoro substituted. For example, R4may be a -OMe, -OCHF2 or -SO2Me group.

[0130] In another embodiment of either of the first or the second aspects of the invention, R4and R7together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0131] Typically, where R4and R7together form a hydrocarbylene group, the hydrocarbylene group, including any optional substituents, contains no more than four carbon atoms.

[0132] Typically, the total number of nitrogen, oxygen and sulphur atoms in any hydrocarbylene group (including any optional substituents) formed by R4and R7is no more than three. More typically, the total number of nitrogen, oxygen and sulphur atoms in any hydrocarbylene group (including any optional substituents) formed by R4and R7is no more than two.

[0133] Typically in such an embodiment, R4and R7together form a C1-C4 saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbylene group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and wherein the hydrocarbylene group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom. Where R4and R7together form a hydrocarbylene group, typically the hydrocarbylene group has a chain length of from 2 to 4 atoms. More typically, the hydrocarbylene group has a chain length of 2 or 3 atoms.

[0134] More typically, where R4and R7together form a hydrocarbylene group, the hydrocarbylene group is selected from -CH2-CH2-, -CH2-O-, -O-CH2-, -CH2-CH2-CH2-, -O-CH2-CH2-, -CH2-CH2-O- or -CH2-O-CH2-, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0135] Typically, where R4and R7together form a hydrocarbylene group, R8is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. More typically, where R4and R7together form a hydrocarbylene group, R8is selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. Yet more typically, where R4and R7together form a hydrocarbylene group, R8is selected from hydrogen or a methyl or fluoromethyl group. More typically still, where R4and R7together form a hydrocarbylene group, R8is hydrogen.

[0136] As stated in accordance with both the first and the second aspects of the invention, R5is selected from hydrogen or a halo group. In one embodiment, R5is selected from hydrogen or a fluoro, chloro or bromo group. More typically, R5is selected from hydrogen or a fluoro group. Most typically, R5is hydrogen.

[0137] As stated in accordance with both the first and the second aspects of the invention, R6is selected from a halo, -R60or -OR60group, wherein R60is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. More typically, R6is selected from a fluoro, chloro, bromo, -R60or -OR60group. More typically still, R6is selected from a -R60or -OR60group.

[0138] In one embodiment, R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. Typically, R60is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. More typically, R60is selected from a methyl, fluoromethyl, ethyl or fluoroethyl group. More typically still, R60is selected from a methyl or fluoromethyl group. In a further embodiment, R6is a methyl or a fluoromethyl group. More typically, R6is a methyl group.

[0139] As stated, in one embodiment of both the first and the second aspects of the invention, R7and R8are each independently selected from hydrogen or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom, or R7and R8together with the carbon atom to which they are attached form a 3- to 10- membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a Ci- C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0140] In one embodiment, R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom, or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0141] In another embodiment, R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom. For example, R7may be selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7that is directly attached to the reminder of the molecule is a carbon atom, and R8may be selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. Typically in such an example, R8is selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, Ci- C4 fluoroalkyl or C3-C4 fluorocycloalkyl group.

[0142] In yet another embodiment, R7and R8are each independently selected from hydrogen or a Ci-Ce saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and wherein the hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom. For example, R7may be selected from hydrogen or a Ci- Ce saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and wherein the hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of any hydrocarbyl group of R7that is directly attached to the reminder of the molecule is a carbon atom, and R8may be selected from hydrogen or a methyl or fluoromethyl group.

[0143] In one embodiment, R7and R8are each independently selected from hydrogen or a -CN, -COOH, -COOR71, -CO-N(R72)2, -L7-COOH, -L7-COOR71, -L7-CO-N(R72)2, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, wherein : each R71is independently selected from a -R73or -R74group; each R72is independently selected from hydrogen or a -R73or -R74group, or any two R72may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; each L7is independently selected from a straight-chained alkylene or alkenylene group, wherein the straight-chained alkylene or alkenylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL7; each RL7is independently selected from a fluoro, methyl or fluoromethyl group; or any two RL7may, together with the atom or atoms to which they are attached, form a 3- to 6-membered monocyclic group, wherein the 3- to 6- membered monocyclic group is saturated or monounsaturated, and wherein the 3- to 6-membered monocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; or any RL7and R71, or any RL7and any R72, may together with the atoms of the -L7-COOR71, -L7-CO-N(R72)2, -L7-OR71or -L7-N(R72)2 group to which they are attached, form a 3- to 6-membered monocyclic heterocyclic group, wherein the 3- to 6-membered monocyclic heterocyclic group is saturated or monounsaturated, and wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; each R73is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4-C6 cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group, wherein the C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4- Ce cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and each R74is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe2, wherein any methyl group of R74may optionally be fluoro substituted; provided that any R7or R8group, including any optional substituents, contains no more than 12 carbon atoms, and that each atom of R7or R8that is directly attached to the reminder of the molecule is a carbon or hydrogen atom.

[0144] Typically in such an embodiment, R7is selected from hydrogen or a -CN, -COOH, -COOR71, -CO-N(R72)2, -L7-COOH, -L7-COOR71, -L7-CO-N(R72)2, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, provided that R7, including any optional substituents, contains no more than 12 carbon atoms, and that the atom of R7that is directly attached to the reminder of the molecule is a carbon or hydrogen atom, and R8is selected from hydrogen or a methyl or fluoromethyl group.

[0145] Thus, for example, R7may be hydrogen or a -R73group such as a methyl, -CF3, ethyl, isopropyl or -CH2CH2CH=CH2 group, or a -COOH group, or a -L7-COOH group such group, or a -L7-COOR71group such as a -CMe2COOMe, -CFhCFhCOOMe or -CFhCOOEt group, or a -L7-CO-N(R72)2 group such as a group, or a -L7-OR71group such as a -CHhOMe group, or a

[0146] -L7-N(R72)2 group such group.

[0147] As will be understood, for example where R7is a -L7-COOH group selected from chained alkylene group substituted with two RL7groups, wherein the two RL7together form a -CH2CH2-, -CH2- or -CF2- group respectively, such that the two RL7and the carbon atom or atoms to which they are attached together form a cyclopropyl or fluorocyclopropyl group. Similarly, where R7is a -L7-N(R72)2 group selected from , L7may be seen as a straight-chained alkylene group substituted with a single RL7group, wherein the RL7and one R72group together form a -CH2CH2- or -CH2CH2CH2- group respectively, such that the RL7and the R72together with the atoms of the -L7-N(R72)2 group to which they are attached together form a saturated 5- or 6-membered monocyclic heterocyclic group.

[0148] Typically in any of the above embodiments, each L7is independently selected from a straight-chained alkylene or alkenylene group, wherein the straight-chained alkylene group optionally includes a single heteroatom selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with a single oxo (=0) group and / or with one or more groups RL. Typically in the above embodiments, any R7or R8group, including any optional substituents, contains no more than 10 carbon atoms. More typically, any R7or R8group, including any optional substituents, contains no more than 8 carbon atoms. More typically still, any R7or R8group, including any optional substituents, contains no more than 6 carbon atoms.

[0149] Typically, the total number of nitrogen, oxygen and sulphur atoms in any R7or R8group, including any optional substituents, is no more than four. More typically, the total number of nitrogen, oxygen and sulphur atoms in any R7or R8group, including any optional substituents, is no more than three.

[0150] In one aspect of the above embodiment:

[0151] R7and R8are each independently selected from hydrogen or a -CN, -COOH, -COOR71, -L7-COOH, -L7-COOR71, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group; each R71is independently selected from a -R73or -R74group; each R72is independently selected from hydrogen or a -R73or -R74group, or any two R72may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each L7is independently selected from a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with one or two oxo ( = 0) groups and / or with one or more groups RL7; each RL7is independently selected from a fluoro, methyl or fluoromethyl group; or any RL7and R71, or any RL7and any R72, may together with the atoms of the -L7-COOR71, -L7-OR71or -L7-N(R72)2group to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and each R73is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or Cs-Ce cycloalkenyl group, wherein the C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or Cs-Ce cycloalkenyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; provided that any R7or R8group, including any optional substituents, contains no more than 8 carbon atoms, and that each atom of R7or R8that is directly attached to the reminder of the molecule is a carbon or hydrogen atom.

[0152] Typically in such an aspect, R7is selected from hydrogen or a -CN, -COOH, -COOR71, -L7-COOH, -L7-COOR71, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, and R8is selected from hydrogen or a methyl or fluoromethyl group.

[0153] Typically in such an aspect, any R7or R8group, including any optional substituents, contains no more than 6 carbon atoms.

[0154] In a further embodiment, R7and R8are each independently selected from hydrogen or a -COOH, -COOR75, -CONH2, -CONHR75, -CON(R75)2, -L71-OH, -L71-OR75, -L71-NH2, -L71-NHR75, -L71-N(R75)2, -L71-COOH, -L71-COOR75, -L71-CONH2, -L71-CONHR75, -L71-CON(R75)2, or -R75group, wherein : each -L71- is independently selected from a -L72- or -L73- group; each -L72- is independently selected from a -CH2-, -CHMe-, -CMe2- or group, wherein any -L72- moiety may optionally be fluoro substituted; each -L73- is independently selected from a -CH2-CH2-, -CH2-CHMe-,

[0155] -CH2-CMe2-, -CHMe-CH2-, -CHMe-CHMe-, -CHMe-CMe2-, -CMe2-CH2-, -CMe2-CHMe-, may optionally be fluoro substituted; and each R75is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-C4 fluoroalkyl, C2-C4 fluoroalkenyl, fluorocyclopropyl, fluorocyclopropylmethyl or fluorocyclobutyl group, or any two R75attached to the same nitrogen atom may together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated monocyclic heterocyclic group, such as an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl group, wherein the 4- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or with one or two methyl groups, wherein said methyl groups may optionally be fluoro-substituted; provided that any R7or R8group, including any optional substituents, contains no more than 12 carbon atoms.

[0156] Typically in such an embodiment, R7is selected from hydrogen or a -COOH, -COOR75, -CONH2, -CONHR75, -CON(R75)2, -L71-OH, -L71-OR75, -L71-NH2, -L71-NHR75, -L71-N(R75)2, -L71-COOH, -L71-COOR75, -L71-CONH2, -L71-CONHR75, -L71-CON(R75)2, or -R75group, and R8is selected from a hydrogen or a fluoro, methyl or fluoromethyl group. More typically, R8is hydrogen.

[0157] Typically, where R7is selected from hydrogen or a -COOH, -COOR75, -CONH2, -CONHR75, -CON(R75)2, -L71-OH, -L71-OR75, -L71-NH2, -L71-NHR75, -L71-N(R75)2, -L71-COOH, -L71-COOR75, -L71-CONH2, -L71-CONHR75, -L71-CON(R75)2, or -R75group, R7(including any optional substituents) contains no more than 10 carbon atoms. More typically, R7(including any optional substituents) contains no more than 8 carbon atoms. More typically still, R7(including any optional substituents) contains no more than 6 carbon atoms.

[0158] In another embodiment, R7and R8are each independently selected from hydrogen or a -COOH, -COOR75, -L71-COOH, -L71-COOR75, -L71-OH, -L71-OR75or -R75group, wherein : each -L71- is independently selected from a -L72- or -L73- group; each -L72- is independently selected from a -CH2-, -CHMe-, -CMe2- or

[0159] T- group, wherein any -L72- moiety may optionally be fluoro substituted;

[0160] „ / \ each -L73- is independently selected from a , -CH2-CH2-,

[0161] -CH2-CHMe-, -CH2-CMe2-, -CHMe-CH2-, -CHMe-CHMe-, -CHMe-CMe2-, -CMe2-CH2-, -CMe2-CHMe- or -CMe2-CMe2- group, wherein any -L73- moiety may optionally be fluoro substituted; and each R75is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-C4 fluoroalkyl, C2-C4 fluoroalkenyl, fluorocyclopropyl, fluorocyclopropylmethyl or fluorocyclobutyl group.

[0162] Typically in such an embodiment, R7is selected from hydrogen or a -COOH, -COOR75, -L71-COOH, -L71-COOR75, -L71-OH, -L71-OR75or -R75group, and R8is selected from hydrogen or a methyl or fluoromethyl group.

[0163] In one aspect of such an embodiment: each -L71- is independently selected from a -CH2-, -CHMe-, -CMe2-, -CH2-CH2-, -CH2-CHMe-, -CH2-CMe2-, -CHMe-CH2-, -CHMe-CHMe-, -CHMe-CMe2-, -CMe2-CH2-, -CMe2-CHMe- or -CMe2-CMe2- group, wherein any -CH2-, -CHMe- or -CMe2- group may optionally be fluoro substituted; and each R75is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, cyclopropyl, cyclobutyl, C1-C4 fluoroalkyl, C2-C4 fluoroalkenyl, fluorocyclopropyl or fluorocyclobutyl group.

[0164] Typically in such an embodiment, each -L71- is independently selected from a -CH2-, -CHMe-, -CMe2-, -CH2-CH2-, -CH2-CHMe-, -CH2-CMe2-, -CHMe-CH2-, -CHMe-CHMe- or -CMe2-CH2- group, wherein any -CH2-, -CHMe- or -CMe2- group may optionally be fluoro substituted. For example, each -L71- may be independently selected from a -CH2-, -CHMe-, -CMe2-, -CH2-CH2-, -CH2-CHMe-, -CH2-CMe2-, -CHMe-CH2-, -CHMe-CHMe- or -CMe2-CH2- group, wherein any -CH2-, -CHMe- or -CMe2- group may optionally be fluoro substituted, and each R75may be independently selected from a C1-C4 alkyl, C2-C4 alkenyl, cyclopropyl, cyclobutyl, C1-C4 fluoroalkyl, C2-C4 fluoroalkenyl, fluorocyclopropyl or fluorocyclobutyl group.

[0165] Typically in such an embodiment, R7including any optional substituents, contains no more than 6 carbon atoms, and R8is selected from a hydrogen or a methyl or fluoromethyl group. More typically, R7including any optional substituents, contains no more than 5 carbon atoms, and R8is selected from a hydrogen or a methyl or fluoromethyl group.

[0166] In another embodiment, R7and R8are each independently selected from hydrogen or a -L71-COOH, -L71-COOR75, -L71-OH, -L71-OR75or -R75group, wherein : each -L71- is independently selected from a -CH2-, -CHMe- or -CMe?- group, wherein any -CH2-, -CHMe- or -CMe2- group may optionally be fluoro substituted; and each R75is independently selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group.

[0167] Typically in such an embodiment, R7is selected from hydrogen or a -L71-COOH, -L71-COOR75, -L71-OH, -L71-OR75or -R75group, and R8is selected from hydrogen or a methyl or fluoromethyl group.

[0168] In another embodiment, R7and R8are each independently selected from hydrogen or a methyl or fluoromethyl group. For example, R7may be selected from hydrogen or a methyl or fluoromethyl group, and R8may be hydrogen.

[0169] In one embodiment, at least one of R7and R8is hydrogen.

[0170] In a further embodiment, R7and R8are both hydrogen.

[0171] In another embodiment of either of the first or the second aspects of the invention, R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0172] Typically in such an embodiment, R7and R8together with the carbon atom to which they are attached form a 3- to 6-membered saturated monocyclic group, such that each ring atom of the saturated monocyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the saturated monocyclic group may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from oxo (=0), -CN, or a C1-C3 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include a single heteroatom selected from N and O in its carbon skeleton.

[0173] For example, R7and R8may together form a group -L78-, wherein -L78- is selected from a -CH2-CH2-, -CH2-CH2-CH2-, -CH2-NH-CH2-, -CH2-O-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-O-CH2-, -CH2-NH-CH2-CH2- or -CH2-O-CH2-CH2- group, and wherein -L78- may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from an oxo (=0), -CN, methyl (Me), -OH, -OMe, -NH2, -NHMe or -NMe2 group, wherein any methyl group of a -L78- substituent may optionally be fluoro substituted.

[0174] As stated in accordance with both the first and the second aspects of the invention, L is selected from a bond, -O-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms.

[0175] In one embodiment of either of the first or the second aspects of the invention, the hydrocarbylene group of L has a chain length of 1 or 2 atoms. For example, L may be selected from a bond, -O-, -NH-, or a C1-C4 alkylene group, wherein the alkylene group may be straight-chained or branched, or be or include a cyclic group, wherein the alkylene group may optionally be substituted with one or more fluoro groups, wherein any carbon atom of the alkylene group that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with an oxo (=0) group, wherein the alkylene group may optionally include a single heteroatom selected from N and O in its carbon skeleton, and wherein the alkylene group has a chain length of 1 or 2 atoms. In a further embodiment of either of the first or the second aspects of the invention, the hydrocarbylene group of L has a chain length of 1 atom. For example, L may be selected from a bond, -O-, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group, or the two RLmay together with the carbon atom to which they are attached form a cyclopropyl group, wherein the cyclopropyl group may optionally be fluoro substituted. Typically in such an embodiment, L is selected from a bond, -NH-, or a -C(RL)2- group. More typically, L is selected from a bond or a -C(RL)2- group.

[0176] In one embodiment of either of the first or the second aspects of the invention, L is a -C(RL)2- group.

[0177] Typically in the above embodiment, each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group. More typically, each RLis independently selected from hydrogen or a fluoro group.

[0178] Most typically, L is selected from a bond or a -CH2- group.

[0179] In a particular embodiment of either of the first or the second aspects of the invention, L is a bond.

[0180] As stated in accordance with both the first and the second aspects of the invention, R10is a 3- to 12-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

[0181] In one embodiment of either of the first or the second aspects of the invention, R10is a 5- to 10-membered aryl or heteroaryl group, wherein the aryl or the heteroaryl group may optionally be substituted with one or more substituents each independently selected from a halo, -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. Typically in such an embodiment, R10is an optionally substituted phenyl or 5- or 6-membered heteroaryl group, such as an optionally substituted phenyl, pyrrolyl, thiophenyl, pyridinyl or pyrazinyl group. In one aspect of such an embodiment, R10is an optionally substituted 5- or 6-membered heteroaryl group.

[0182] Typically, where R10is a 5- to 10-membered aryl or heteroaryl group, such as a phenyl or 5- or 6-membered heteroaryl group, the ring atom of the aryl or heteroaryl group that is directly attached to L is a carbon atom.

[0183] As stated, the cyclic group of R10may optionally be substituted with one or more substituents each independently selected from a halo, oxo ( = 0), -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci-Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety. Typically, where the cyclic group of R10is a 5- to 10-membered aryl or heteroaryl group, the aryl or the heteroaryl group may optionally be substituted with one or more substituents each independently selected from a halo, -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci- Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety.

[0184] In one embodiment of either of the first or the second aspects of the invention, the cyclic group of R10is optionally substituted with one or more halo groups and / or with one or two non-halo substituents each independently selected from an oxo (=0), -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci-Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety. Typically in such an embodiment, the cyclic group of R10is substituted with one or two non-halo substituents, and optionally with one or more halo groups.

[0185] For example, where the cyclic group of R10is a 5- to 10-membered aryl or heteroaryl group, the aryl or the heteroaryl group may optionally be substituted with one or more halo groups and / or with one or two non-halo substituents each independently selected from a -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci-Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety. Typically in such an embodiment, the aryl or the heteroaryl group of R10is substituted with one or two non-halo substituents, and optionally with one or more halo groups.

[0186] In one embodiment of either of the first or the second aspects of the invention, the cyclic group of R10is optionally substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two non-halo substituents each independently selected from an -OH, -SH, -NH2, -CN, or a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton. Typically in such an embodiment, the cyclic group of R10is a 5- to 10-membered aryl or heteroaryl group, such as a phenyl or 5- or 6-membered heteroaryl group. Typically in such an embodiment, the cyclic group of R10is substituted with one or two non-halo substituents, and optionally with one or more fluoro, chloro and / or bromo groups.

[0187] In a further embodiment of either of the first or the second aspects of the invention, the cyclic group of R10is optionally substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two non-halo substituents each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. Typically in such an embodiment, the cyclic group of R10is a 5- to 10- membered aryl or heteroaryl group, such as a phenyl or 5- or 6-membered heteroaryl group. Typically in such an embodiment, the cyclic group of R10is substituted with one or two non-halo substituents, and optionally with one or more fluoro, chloro and / or bromo groups.

[0188] In one embodiment of either of the first or the second aspects of the invention, the cyclic group of R10is unsubstituted. For example, R10may be an unsubstituted 5- to 10-membered aryl or heteroaryl group, such as an unsubstituted phenyl or 5- or 6- membered heteroaryl group. In one aspect of such an embodiment, R10is an unsubstituted 5- or 6-membered heteroaryl group.

[0189] In another embodiment of either of the first or the second aspects of the invention, the cyclic group of R10is substituted with at least one -CN, fluoromethyl or fluoromethoxy group. Typically in such an embodiment, the cyclic group of R10is substituted with at least one -CN group. For example, the cyclic group of R10may be substituted with one -CN, fluoromethyl or fluoromethoxy group (typically a -CN group), and may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and / or with a single additional substituent selected from an -OH, -SH, -NH2, or a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton. Typically in such an embodiment, the cyclic group of R10is a 5- to 10-membered aryl or heteroaryl group, such as a phenyl or 5- or 6-membered heteroaryl group. Typically in such an embodiment, the single additional substituent, where present, is selected from a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0190] Where the cyclic group of R10is a phenyl or a 6-membered heteroaryl group substituted with at least one -CN, fluoromethyl or fluoromethoxy group, typically one -CN, fluoromethyl or fluoromethoxy group is located at the 3-, 4- or 5-position, relative to the point of attachment of the phenyl or the 6-membered heteroaryl ring to L. More typically, one -CN, fluoromethyl or fluoromethoxy group is located at the 3- or 5-position, relative to the point of attachment of the phenyl or the 6- membered heteroaryl ring to L.

[0191] Where the cyclic group of R10is a 5-membered heteroaryl group substituted with at least one -CN, fluoromethyl or fluoromethoxy group, typically one -CN, fluoromethyl or fluoromethoxy group is located at the 3- or 4-position, relative to the point of attachment of the 5-membered heteroaryl ring to L.

[0192] In one embodiment of the first aspect of the invention, the compound is a compound of Formula (III): wherein :

[0193] L10is selected from a bond, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group;

[0194] X2is selected from N, C-H, C-Hal and C-RX2;

[0195] X3is selected from N, C-H, C-Hal and C-RX3;

[0196] X4is selected from N, C-H, C-Hal and C-RX4;

[0197] X5is selected from N, C-H, C-Hal and C-RX5;

[0198] X6is selected from N, C-H, C-Hal and C-RX6; no more than three of X2, X3, X4, X5and X6are N; each Hal is independently selected from F, Cl and Br;

[0199] RX2, RX3, RX4, RX5and RX6are each independently selected from -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci-Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety; and

[0200] R1, R2, Q3, R4, R5, R6, R7, R8and R9are as defined in accordance with Formula (I).

[0201] In one aspect of such an embodiment, Q3is C-R3, i.e. the compound has the Formula (Illa):

[0202] Formula (Illa) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, L10, X2, X3, X4, X5and X6are as defined in accordance with Formula (III).

[0203] Typically in such an aspect:

[0204] R2is selected from hydrogen or a halo group; and

[0205] R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0206] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0207] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0208] R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; or R3and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0209] In another aspect of such an embodiment, Q3is N, i.e. the compound has the Formula (Illb):

[0210] Formula (Illb) wherein R1, R2, R4, R5, R6, R7, R8, R9, L10, X2, X3, X4, X5and X6are as defined in accordance with Formula (III).

[0211] Typically in such an aspect, RX2, RX3, RX4, RX5and RX6are each independently selected from -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

[0212] In a corresponding embodiment of the second aspect of the invention, the compound is a compound of Formula (IV) :

[0213] Formula (IV) wherein :

[0214] L10is selected from a bond, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group;

[0215] X2is selected from N, C-H, C-Hal and C-RX2;

[0216] X3is selected from N, C-H, C-Hal and C-RX3;

[0217] X4is selected from N, C-H, C-Hal and C-RX4;

[0218] X5is selected from N, C-H, C-Hal and C-RX5;

[0219] X6is selected from N, C-H, C-Hal and C-RX6; no more than three of X2, X3, X4, X5and X6are N; each Hal is independently selected from F, Cl and Br;

[0220] RX2, RX3, RX4, RX5and RX6are each independently selected from -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci-Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety; and

[0221] R1, R4, R5, R6, R7, R8, R9, R14, R15, R16and R17are as defined in accordance with Formula (II).

[0222] Typically in such an embodiment:

[0223] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0224] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0225] R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; each R14and R15is independently selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;

[0226] R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0227] R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted; or R17and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0228] Typically where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), L10is selected from a bond or a -CH2- group. More typically, L10is a bond.

[0229] In one embodiment where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), each Hal is F.

[0230] Typically where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), no more than two of X2, X3, X4, X5and X6are N.

[0231] Typically where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), at least two of X2, X3, X4, X5and X6are selected from N, C-H and C-Hal. More typically, at least three of X2, X3, X4, X5and X6are selected from N, C-H and C-Hal.

[0232] In one embodiment where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), at least two of X2, X3, X4, X5and X6are selected from N and C-H. More typically, at least three of X2, X3, X4, X5and X6are selected from N and C-H, provided that no more than two of X2, X3, X4, X5and X6are N.

[0233] In another embodiment where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), X2is selected from N, C-H and C-Hal, X3is selected from N, C-H and C-Hal, X4is selected from N, C-H and C-Hal, X5is selected from N, C-H and C-Hal, and X6is selected from N, C-H and C-Hal. Typically in such an embodiment, X2is selected from N and C-H, X3is selected from N and C-H, X4is selected from N and C-H, X5is selected from N and C-H, and X6is selected from N and C-H, provided that no more than two of X2, X3, X4, X5and X6are N. Typically in such an embodiment, at least one of X2, X3, X4, X5and X6is N. More typcially, two of X2, X3, X4, X5and X6are N. For example, X2may be C-H, X3may be N, X4may be C-H, X5may be C-H, and X6may be N.

[0234] In another embodiment where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), at least one of X2, X3, X4, X5and X6is C-RX2, C-RX3, C-RX4, C-RX5or C-RX6. Typically in such an embodiment, at least two of X2, X3, X4, X5and X6are selected from N, C-H and C-Hal. More typically, at least three of X2, X3, X4, X5and X6are selected from N, C-H and C-Hal. For example, at least three of X2, X3, X4, X5and X6may be selected from N and C-H, provided that no more than two of X2, X3, X4, X5and X6are N.

[0235] In one embodiment where the compound is a compound of Formula (III), (Illa), (Illb) or (IV), RX2, RX3, RX4, RX5and RX6are each independently selected from an -OH, -SH, -NH2, -CN, or a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton. Typically, RX2, RX3, RX4, RX5and RX6are each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically, RX2, RX3, RX4, RX5and RX6are each independently selected from a -CN or a Ci-Ce or C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. In a further embodiment where the compound is a compound of Formula (III), (Illa), (Illb) or (IV) : one of X3, X4and X5is C-CN, -C-RFor -C-ORF, wherein RFis a fluoromethyl group; optionally one of X2, X3, X5and X6is C-RX2, C-RX3, C-RX5or C-RX6, wherein RX2, RX3, RX5and RX6are each independently selected from a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton; and each remaining X2, X3, X4, X5and X6is independently selected from N, C-H and C-Hal.

[0236] In one aspect of such an embodiment: one of X3, X4and X5is C-CN; optionally one of X2, X3, X5and X6is C-RX2, C-RX3, C-RX5or C-RX6; and each remaining X2, X3, X4, X5and X6is independently selected from N, C-H and C-Hal.

[0237] Typically in such an embodiment:

[0238] X2is C-H, C-Hal or C-RX2; one of X3and X4is C-CN, -C-RFor -C-ORF; and each remaining X3, X4, X5and X6is independently selected from N, C-H and C-Hal, provided that no more than two of X3, X4, X5and X6are N.

[0239] More typically in such an embodiment, e.g. when L10is a bond :

[0240] X2is C-H, C-Hal or C-RX2;

[0241] X3is C-CN, -C-RFor -C-ORF; and

[0242] X4, X5and X6are each independently selected from N, C-H and C-Hal, provided that no more than one of X4, X5and X6is N. For example, X2may be C-H or C-RX2, X4may be C-H, X5may be C-H and X6may be C-H or N.

[0243] Typically in such an embodiment, RX2, RX3, RX5and RX6are each independently selected from a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically in such an embodiment, RX2, RX3, RX5and RX6are each independently selected from a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically in such an embodiment, RX2, RX3, RX5and RX6are each independently selected from a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0244] In another embodiment of the first aspect of the invention, the compound is a compound of Formula (V): wherein :

[0245] L10is selected from a bond, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group;

[0246] A1is selected from N or C;

[0247] A2is selected from N, O, S, N-H, C-H, C-Hal, N-RN2and C-RA2;

[0248] A3is selected from N, O, S, N-H, C-H, C-Hal, N-RN3and C-RA3;

[0249] A4is selected from N, O, S, N-H, C-H, C-Hal, N-RN4and C-RA4; and A5is selected from N, O, S, N-H, C-H, C-Hal, N-RN5and C-RA5; such that A1, A2, A3, A4and A5together form a 5-membered aromatic ring; each Hal is independently selected from F, Cl and Br;

[0250] RN2, RN3, RN4and RN5are each independently selected from a C1-C12 (e.g. Ci- Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2, N-RN3, N-RN4or N-RN5is a carbon atom;

[0251] RA2, RA3, RA4and RA5are each independently selected from -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci-Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety; and

[0252] R1, R2, Q3, R4, R5, R6, R7, R8and R9are as defined in accordance with Formula (I).

[0253] In one aspect of such an embodiment, Q3is C-R3, i.e. the compound has the Formula (Va) :

[0254]

[0255] Formula (Va) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, L10, A1, A2, A3, A4and A5are as defined in accordance with Formula (V).

[0256] Typically in such an aspect:

[0257] R2is selected from hydrogen or a halo group; and

[0258] R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0259] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0260] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0261] R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; or R3and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0262] In another aspect of such an embodiment, Q3is N, i.e. the compound has the Formula (Vb):

[0263] Formula (Vb) wherein R1, R2, R4, R5, R6, R7, R8, R9, L10, A1, A2, A3, A4and A5are as defined in accordance with Formula (V).

[0264] Typically in such an aspect:

[0265] RN2, RN3, RN4and RN5are each independently selected from a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2, N-RN3, N-RN4or N-RN5is a carbon atom; and

[0266] RA2, RA3, RA4and RA5are each independently selected from -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

[0267] In a corresponding embodiment of the second aspect of the invention, the compound is a compound of Formula (VI) : wherein :

[0268] L10is selected from a bond, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group;

[0269] A1is selected from N or C;

[0270] A2is selected from N, O, S, N-H, C-H, C-Hal, N-RN2and C-RA2;

[0271] A3is selected from N, O, S, N-H, C-H, C-Hal, N-RN3and C-RA3;

[0272] A4is selected from N, O, S, N-H, C-H, C-Hal, N-RN4and C-RA4; and

[0273] A5is selected from N, O, S, N-H, C-H, C-Hal, N-RN5and C-RA5; such that A1, A2, A3, A4and A5together form a 5-membered aromatic ring; each Hal is independently selected from F, Cl and Br;

[0274] RN2, RN3, RN4and RN5are each independently selected from a C1-C12 (e.g. Ci- Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2, N-RN3, N-RN4or N-RN5is a carbon atom;

[0275] RA2, RA3, RA4and RA5are each independently selected from -OH, -SH, -NH2, -SO2NH2, or a C1-C12 (e.g. Ci-Cs) saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety; and

[0276] R1, R4, R5, R6, R7, R8, R9, R14, R15, R16and R17are as defined in accordance with Formula (II).

[0277] Typically in such an embodiment:

[0278] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0279] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0280] R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; each R14and R15is independently selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;

[0281] R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0282] R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted; or R17and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom . Typically where the compound is a compound of Formula (V), (Va), (Vb) or (VI), when A1is N, L10is not -NH-.

[0283] In one embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI), A1is C.

[0284] Typically where the compound is a compound of Formula (V), (Va), (Vb) or (VI), L10is selected from a bond or a -CH2- group. More typically, L10is a bond.

[0285] In one embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI), each Hal is F.

[0286] Typically where the compound is a compound of Formula (V), (Va), (Vb) or (VI), the 5-membered aromatic ring formed by A1, A2, A3, A4and A5contains at least two ring carbon atoms. More typically, the 5-membered aromatic ring formed by A1, A2, A3, A4and A5contains at least three ring carbon atoms.

[0287] Typically where the compound is a compound of Formula (V), (Va), (Vb) or (VI), the total number of ring nitrogen, oxygen and sulphur atoms in the 5-membered aromatic ring formed by A1, A2, A3, A4and A5is no more than three, and the total number of ring oxygen and sulphur atoms in the 5-membered aromatic ring formed by A1, A2, A3, A4and A5is no more than one. For example, the 5-membered aromatic ring formed by A1, A2, A3, A4and A5may contain :

[0288] (i) one ring nitrogen atom and four ring carbon atoms; or

[0289] (ii) one ring oxygen atom and four ring carbon atoms; or

[0290] (iii) one ring sulphur atom and four ring carbon atoms; or

[0291] (iv) two ring nitrogen atoms and three ring carbon atoms; or

[0292] (v) one ring nitrogen atom, one ring oxygen atom, and three ring carbon atoms; or

[0293] (vi) one ring nitrogen atom, one ring sulphur atom, and three ring carbon atoms; or

[0294] (vii) three ring nitrogen atoms and two ring carbon atoms; or

[0295] (viii) two ring nitrogen atoms, one ring oxygen atom, and two ring carbon atoms; or

[0296] (ix) two ring nitrogen atoms, one ring sulphur atom, and two ring carbon atoms. Typically where the compound is a compound of Formula (V), (Va), (Vb) or (VI), at least two of A2, A3, A4and A5are selected from N, O, S, N-H, C-H and C-Hal.

[0297] In one embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI), A2is selected from N, O, S, N-H, C-H and C-Hal, A3is selected from N, O, S, N-H, C-H, and C-Hal, A4is selected from N, O, S, N-H, C-H and C-Hal, and A5is selected from N, O, S, N-H, C-H and C-Hal.

[0298] In another embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI), at least one of A2, A3, A4and A5is selected from N-RN2, C-RA2, N-RN3, C-RA3, N-RN4, C-RA4, N-RN5and C-RA5. Typically in such an embodiment, at least two of A2, A3, A4and A5are selected from N, O, S, N-H, C-H and C-Hal.

[0299] In one embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI), RN2, RN3, RN4and RN5are each independently selected from a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo ( = 0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2, N-RN3, N-RN4or N-RN5is a carbon atom. Typically, RN2, RN3, RN4and RN5are each independently selected from a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2, N-RN3, N-RN4or N-RN5is a carbon atom. More typically, RN2, RN3, RN4and RN5are each independently selected from a Ci-Ce or C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2, N-RN3, N-RN4or N-RN5is a carbon atom. More typically still, RN2, RN3, RN4and RN5are each independently selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. Yet more typically, RN2, RN3, RN4and RN5are each independently selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, Ci- C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group, more typically a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, such as a methyl or a fluoromethyl group.

[0300] In one embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI), RA2, RA3, RA4and RA5are each independently selected from an -OH, -SH, -NH2, -CN, or a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton. Typically, RA2, RA3, RA4and RA5are each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton. More typically, RA2, RA3, RA4and RA5are each independently selected from a -CN or a Ci- Ce or C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0301] In a further embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI):

[0302] A1is selected from N or C; one of A3and A4is C-CN, -C-RFor -C-ORF, wherein RFis a fluoromethyl group; optionally one of A2and A5is N-RN2, N-RN5, C-RA2or C-RA5, wherein RN2, RN5, RA2and RA5are each independently selected from a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2or N-RN5is a carbon atom; and each remaining A2, A3, A4and A5is independently selected from N, O, S, N-H, C-H and C-Hal; such that A1, A2, A3, A4and A5together form a 5-membered aromatic ring containing at least two ring carbon atoms.

[0303] Typically in such an embodiment, one of A3and A4is C-CN; optionally one of A2and A5is N-RN2, N-RN5, C-RA2or C-RA5; and each remaining A2, A3, A4and A5is independently selected from N, O, S, N-H, C-H and C-Hal.

[0304] Typically in such an embodiment, RN2, RN5, RA2and RA5are each independently selected from a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2or N-RN5is a carbon atom. More typically, RN2, RN5, RA2and RA5are each independently selected from a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2or N-RN5is a carbon atom. More typically still, RN2, RN5, RA2and RA5are each independently selected from a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbyl group that is directly attached to the nitrogen atom of N-RN2or N-RN5is a carbon atom. Yet more typically, RN2, RN5, RA2and RA5are each independently selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group, such as a methyl or a fluoromethyl group.

[0305] In another embodiment where the compound is a compound of Formula (V), (Va), (Vb) or (VI), for example where L10is a bond :

[0306] A1is C;

[0307] A2is selected from O, S, N-H or N-RN2;

[0308] A3is C-CN, -C-RFor -C-ORF, wherein RFis a fluoromethyl group; A4is C-H or C-Hal; and A4is C-H or C-Hal; such that A1, A2, A3, A4and A5together form a 5-membered aromatic ring.

[0309] Typically in such an embodiment:

[0310] A2is selected from S or N-RN2;

[0311] A3is C-CN; A4is C-H; and A4is C-H.

[0312] Typically in such an embodiment, RN2is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group, such as a methyl or a fluoromethyl group.

[0313] As stated in accordance with the second aspect of the invention, R14is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group, and R15is selected from hydrogen or a -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted.

[0314] In one embodiment of the second aspect of the invention, R14is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group, and R15is selected from hydrogen or a -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety. Typically in such an embodiment, R15is selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

[0315] In another embodiment of the second aspect of the invention, R14is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group, and R15is selected from hydrogen or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N and O in its carbon skeleton.

[0316] More typically, each R14and R15is independently selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group.

[0317] In one embodiment, each R14and R15is independently selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, or R14and R15together with the carbon atom to which they are attached form a 3- to 6- membered cyclic group, wherein the cyclic group may optionally by substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted. Typically in such an embodiment, each R14and R15is independently selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group.

[0318] In a further embodiment, R14is hydrogen and R15is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group. For example, R14may be hydrogen and R15may be selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group.

[0319] In a more typical embodiment, each R14and R15is independently selected from hydrogen or a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. For example, R14may be hydrogen and R15may be selected from hydrogen or a Ci- C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. More typically in such an embodiment, each R14and R15is independently selected from hydrogen or a methyl or fluoromethyl group. For example, R14may be hydrogen and R15may be selected from hydrogen or a methyl or fluoromethyl group. In one embodiment, R14and R15are both hydrogen.

[0320] In another embodiment, R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally by substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted. Typically in such an embodiment, R14and R15together with the carbon atom to which they are attached form a 3- to 5- membered saturated monocyclic group wherein the saturated monocyclic group may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from oxo (=0) or a methyl or fluoromethyl group. For example, R14and R15together with the carbon atom to which they are attached may form a cyclopropyl or a cyclobutyl group, wherein the cyclopropyl or cyclobutyl group may optionally be substituted with one or more fluoro groups.

[0321] As stated, in one embodiment of the second aspect of the invention, R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, and R17is selected from hydrogen or a fluoro, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group, or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally by substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted. Typically in such an embodiment, R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, and R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally by substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted.

[0322] In one embodiment, R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, and R17is selected from hydrogen or a fluoro, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. Typically in such an embodiment, R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group.

[0323] In one aspect of such an embodiment, R16is selected from hydrogen or a fluoro, -R160, -CN, -CHO, -COR160, -CO2H or -CO2R160group, wherein R160is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group, and R17is selected from hydrogen or a fluoro, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. Typically in such an aspect, R160is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, and R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. In one embodiment of such an aspect, R17is selected from hydrogen or a fluoro, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. For example, R16may be selected from hydrogen or a fluoro, -R160, -CN, -CHO, -COR160, -CO2H or -CO2R160group, and R17may be hydrogen. Typically in such an aspect, R160is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. More typically in such an aspect, R160is selected from a methyl or fluoromethyl group.

[0324] In another aspect of such an embodiment, R16is selected from hydrogen or a fluoro, -CN, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group, and R17is selected from hydrogen or a fluoro, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group. For example, R16may be selected from hydrogen or a fluoro, -CN, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group, and R17may be hydrogen. Typically in such an aspect, R16is selected from hydrogen or a fluoro, -CN, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, and R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. For example, R16may be selected from hydrogen or a fluoro, -CN, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, and R17may be hydrogen. More typically in such an aspect, R16is selected from hydrogen or a fluoro, -CN, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group, and R17is selected from hydrogen or a fluoro, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. For example, R16may be selected from hydrogen or a fluoro, -CN, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group, and R17may be hydrogen. More typically in such an aspect, each R16and R17is independently selected from hydrogen or a methyl or fluoromethyl group. For example, R16may be selected from hydrogen or a methyl or fluoromethyl group and R17may be hydrogen.

[0325] In one embodiment, R16and R17are both hydrogen.

[0326] In another embodiment, R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally by substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted. Typically in such an embodiment, R16and R17together with the carbon atom to which they are attached form a 3- to 5- membered saturated monocyclic group wherein the saturated monocyclic group may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from oxo (=0) or a methyl or fluoromethyl group. For example, R16and R17together with the carbon atom to which they are attached may form a cyclopropyl or a cyclobutyl group, wherein the cyclopropyl or cyclobutyl group may optionally be substituted with one or more fluoro groups.

[0327] In one embodiment of the second aspect of the invention:

[0328] R16is selected from hydrogen or a fluoro, -CN, C1-C3 alkyl, cyclopropyl, Ci- C3 fluoroalkyl or fluorocyclopropyl group; and

[0329] R17is selected from hydrogen or a fluoro, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group; or R16and R17together with the carbon atom to which they are attached form a cyclopropyl or a cyclobutyl group, wherein the cyclopropyl or cyclobutyl group may optionally be substituted with one or more fluoro groups.

[0330] In another embodiment of the second aspect of the invention, R17and R7together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0331] Typically, where R17and R7together form a hydrocarbylene group, the hydrocarbylene group, including any optional substituents, contains no more than four carbon atoms.

[0332] Typically, the total number of nitrogen, oxygen and sulphur atoms in any hydrocarbylene group (including any optional substituents) formed by R17and R7is no more than three. More typically, the total number of nitrogen, oxygen and sulphur atoms in any hydrocarbylene group (including any optional substituents) formed by R17and R7is no more than two. Typically in such an embodiment, R17and R7together form a C1-C4 saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, and wherein the hydrocarbylene group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0333] Where R17and R7together form a hydrocarbylene group, typically the hydrocarbylene group has a chain length of from 1 to 3 atoms. More typically, the hydrocarbylene group has a chain length of 1 or 2 atoms.

[0334] More typically, where R17and R7together form a hydrocarbylene group, the hydrocarbylene group is selected from -CH2-, -CH2-CH2-, -CH=CH-, -CH2-O- or -O-CH2-, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom.

[0335] Typically, where R17and R7together form a hydrocarbylene group, R8is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. More typically, where R17and R7together form a hydrocarbylene group, R8is selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. Yet more typically, where R17and R7together form a hydrocarbylene group, R8is selected from hydrogen or a methyl or fluoromethyl group. More typically still, where R17and R7together form a hydrocarbylene group, R8is hydrogen.

[0336] Typically, where R17and R7together form a hydrocarbylene group, R16is selected from hydrogen or a fluoro, -CN, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, Ci- C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group. More typically, where R17and R7together form a hydrocarbylene group, R16is selected from hydrogen or a fluoro, -CN, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group. Yet more typically, where R17and R7together form a hydrocarbylene group, R16is selected from hydrogen or a fluoro, -CN, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group. More typically still, where R17and R7together form a hydrocarbylene group, R16is selected from hydrogen or a methyl or fluoromethyl group. Yet more typically, where R17and R7together form a hydrocarbylene group, R16is hydrogen.

[0337] As will be understood, insofar as practical, embodiments directed to one substituent or moiety (such as a given R or X group) may be read in conjunction with embodiments directed to a different substituent or moiety.

[0338] For example, in a first exemplary embodiment, there is provided a compound of Formula (I) as defined above, wherein :

[0339] R1is hydrogen;

[0340] R2is selected from hydrogen or a halo, -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0341] Q3is selected from N or C-R3;

[0342] R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0343] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0344] R5is selected from hydrogen or a halo group;

[0345] R6is selected from a halo, -R60or -OR60group, wherein R60is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group;

[0346] R7and R8are each independently selected from hydrogen or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton;

[0347] R9is hydrogen;

[0348] L is selected from a bond, -O-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; and

[0349] R10is a 5- to 10-membered aryl or heteroaryl group, wherein the aryl or the heteroaryl group may optionally be substituted with one or more substituents each independently selected from a halo, -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety.

[0350] In one aspect of the first exemplary embodiment, Q3is C-R3, i.e. the compound has the formula (la) as defined above. Typically in such an aspect:

[0351] R2is selected from hydrogen or a halo group;

[0352] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0353] R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0354] In another aspect of the first exemplary embodiment, Q3is N, i.e. the compound has the formula (lb) as defined above. Typically in such an aspect:

[0355] (i) L is selected from -O-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; and / or

[0356] (ii) R10is a 5- to 10-membered aryl or heteroaryl group, wherein the aryl or the heteroaryl group may optionally be substituted with one or more substituents each independently selected from a halo, -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; and / or

[0357] (iii) the 5- to 10-membered aryl or heteroaryl group of R10is substituted with at least one -CN, fluoromethyl or fluoromethoxy group; and / or

[0358] (iv) R10is a 5- or 6-membered heteroaryl group, wherein the heteroaryl group may optionally be substituted with one or more substituents each independently selected from a halo, -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

[0359] In a corresponding second exemplary embodiment, there is provided a compound of Formula (II) as defined above, wherein:

[0360] R1is hydrogen;

[0361] R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0362] R5is selected from hydrogen or a halo group;

[0363] R6is selected from a halo, -R60or -OR60group, wherein R60is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group;

[0364] R7and R8are each independently selected from hydrogen or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton;

[0365] R9is hydrogen;

[0366] R14is elected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group; and

[0367] R15is selected from hydrogen or a -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;

[0368] R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety;

[0369] R17is selected from hydrogen or a fluoro, C1-C4 alkyl, cyclopropylmethyl, C3- C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;

[0370] L is selected from a bond, -O-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S( = NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; and

[0371] R10is a 5- to 10-membered aryl or heteroaryl group, wherein the aryl or the heteroaryl group may optionally be substituted with one or more substituents each independently selected from a halo, -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety.

[0372] In one aspect of the second exemplary embodiment:

[0373] R60is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0374] R7and R8are each independently selected from hydrogen or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; each R14and R15is independently selected from hydrogen or a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group, or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;

[0375] R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO(=NH)- moiety; and

[0376] R17is selected from hydrogen or a fluoro, C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted. In a third exemplary embodiment, there is provided a compound of Formula (I) as defined above, wherein :

[0377] R1is hydrogen;

[0378] R2is selected from hydrogen or a fluoro, chloro, bromo, methyl or fluoromethyl group;

[0379] R3is selected from hydrogen or a fluoro, chloro, bromo, -R30, -CH2R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0380] R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)2, -SO2-R41, -SO2-N(R42)2, -L4-OH, -L4-OR41, -L4-N(R42)2, -L4-SO2-R41, -L4-SO2-N(R42)2, -O-L4-OH, -O-L4-OR41, -O-L4-N(R42)2, -O-L4-SO2-R41, -O-L4-SO2-N(R42)2, -NR43-L4-OH, -NR43-L4-OR41, -NR43-L4-N(R42)2, -NR43-L4-SO2-R41, -NR43-L4-SO2-N(R42)2, -SO2-L4-OH, -SO2-L4-OR41, -SO2-L4-N(R42)2, -R44, -R45or -L4-R45group, provided that R4, including any optional substituents, contains no more than 8 carbon atoms;

[0381] R41is selected from a -R44or -R45group; each R42is independently selected from hydrogen or a -R44or -R45group, or any two R42may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0382] L4is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L4has a chain length of from 1 to 4 atoms, and wherein L4may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL4; each RL4is independently selected from a fluoro, methyl or fluoromethyl group; or any RL4and R41, or any RL4and any R42, may together with the atoms to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0383] R43is selected from hydrogen or a -R44group; each R44is independently selected from a C1-C4 alkyl, C3-C6 cycloalkyl or C4- Ce cycloalkylalkyl group, wherein the C1-C4 alkyl, C3-C6 cycloalkyl or C4-C6 cycloalkylalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R45is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe?, wherein any methyl group of R45may optionally be fluoro substituted;

[0384] R5is selected from hydrogen or a fluoro, chloro or bromo group;

[0385] R6is selected from a -R60or -OR60group;

[0386] R60is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0387] R7is selected from hydrogen or a -CN, -COOH, -COOR71, -CO-N(R72)2, -L7-COOH, -L7-COOR71, -L7-CO-N(R72)2, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, provided that R7, including any optional substituents, contains no more than 8 carbon atoms, and that the atom of R7that is directly attached to the reminder of the molecule is a carbon or hydrogen atom;

[0388] R71is selected from a -R73or -R74group; each R72is independently selected from hydrogen or a -R73or -R74group, or any two R72may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0389] L7is a straight-chained alkylene or alkenylene group, wherein the straight- chained alkylene or alkenylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL7; each RL7is independently selected from a fluoro, methyl or fluoromethyl group; or any two RL7may, together with the atom or atoms to which they are attached, form a 3- to 6-membered monocyclic group, wherein the 3- to 6- membered monocyclic group is saturated or monounsaturated, and wherein the 3- to 6-membered monocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; or any RL7and R71, or any RL7and any R72, may together with the atoms of the -L7-COOR71, -L7-CO-N(R72)2, -L7-OR71or -L7-N(R72)2 group to which they are attached, form a 3- to 6-membered monocyclic heterocyclic group, wherein the 3- to 6-membered monocyclic heterocyclic group is saturated or monounsaturated, and wherein the 3- to 6-membered monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; each R73is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4-C6 cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group, wherein the C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4- Ce cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R74is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe2, wherein any methyl group of R74may optionally be fluoro substituted;

[0390] R8is selected from a hydrogen or a methyl or fluoromethyl group; or R7and R8together form a group -L78-, wherein -L78- is selected from a -CH2-CH2-, -CH2-CH2-CH2-, -CH2-NH-CH2-, -CH2-O-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-O-CH2-, -CH2-NH-CH2-CH2- or -CH2-O-CH2-CH2- group, wherein -L78- may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from an oxo (=0), -CN, methyl (Me), -OH, -OMe, -NH2, -NHMe or -NMe2 group, and wherein any methyl group of a -L78- substituent may optionally be fluoro substituted;

[0391] R9is hydrogen;

[0392] L is selected from a bond, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group, or the two RLmay together with the carbon atom to which they are attached form a cyclopropyl group, wherein the cyclopropyl group may optionally be fluoro substituted; and

[0393] R10is a 5- to 10-membered aryl or heteroaryl group, wherein the aryl or the heteroaryl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two non-halo substituents each independently selected from an -OH, -SH, -NH2, -CN, or a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton.

[0394] In one aspect of the third exemplary embodiment, Q3is N, i.e. the compound has the formula (lb) as defined above.

[0395] In another aspect of the third exemplary embodiment, Q3is C-R3, i.e. the compound has the formula (la) as defined above. Typically in such an aspect:

[0396] R2is selected from hydrogen or a fluoro, chloro or bromo group;

[0397] R3is selected from hydrogen or a fluoro, chloro, bromo, -R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group;

[0398] R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)2, -SO2-R41, -SO2-N(R42)2, -L4-OH, -L4-OR41, -L4-N(R42)2, -L4-SO2-R41, -L4-SO2-N(R42)2, -O-L4-OH, -O-L4-OR41, -O-L4-N(R42)2, -O-L4-SO2-R41, -O-L4-SO2-N(R42)2, -NR43-L4-OH, -NR43-L4-OR41, -NR43-L4-N(R42)2, -NR43-L4-SO2-R41, -NR43-L4-SO2-N(R42)2, -R44, -R45or -L4-R45group, provided that R4, including any optional substituents, contains no more than 8 carbon atoms;

[0399] R41is selected from a -R44or -R45group; each R42is independently selected from hydrogen or a -R44or -R45group, or any two R42may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each RL4is independently selected from a fluoro, methyl or fluoromethyl group; or any RL4and R41, or any RL4and any R42, may together with the atoms to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R44is independently selected from a C1-C4 alkyl or C3-C6 cycloalkyl group, wherein the C1-C4 alkyl or C3-C6 cycloalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups;

[0400] R7is selected from hydrogen or a -CN, -COOH, -COOR71, -L7-COOH, -L7-COOR71, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, provided that R7, including any optional substituents, contains no more than 8 carbon atoms, and that the atom of R7that is directly attached to the reminder of the molecule is a carbon or hydrogen atom;

[0401] R71is selected from a -R73or -R74group; each R72is independently selected from hydrogen or a -R73or -R74group, or any two R72may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups;

[0402] L7is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL7; each RL7is independently selected from a fluoro, methyl or fluoromethyl group; or any RL7and R71, or any RL7and any R72, may together with the atoms of the -L7-COOR71, -L7-OR71or -L7-N(R72)2 group to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R73is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or Cs-Ce cycloalkenyl group, wherein the C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or Cs-Ce cycloalkenyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and

[0403] R8is selected from a hydrogen or a methyl or fluoromethyl group; or R7and R8together form a group -L78-, wherein -L78- is selected from a -CH2-CH2-, -CH2-CH2-CH2-, -CH2-NH-CH2-, -CH2-O-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-O-CH2-, -CH2-NH-CH2-CH2- or -CH2-O-CH2-CH2- group, wherein -L78- may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from an oxo (=0), -CN, methyl (Me), -OH, -OMe, -NH2, -NHMe or -NMe? group, and wherein any methyl group of a -L78- substituent may optionally be fluoro substituted.

[0404] In a corresponding fourth exemplary embodiment, there is provided a compound of Formula (II) as defined above, wherein :

[0405] R1is hydrogen;

[0406] R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)?, -SO2-R41, -SO2-N(R42)2, -L4-OH, -L4-OR41, -L4-N(R42)2, -L4-SO2-R41, -L4-SO2-N(R42)2, -O-L4-OH, -O-L4-OR41, -O-L4-N(R42)2, -O-L4-SO2-R41, -O-L4-SO2-N(R42)2, -NR43-L4-OH, -NR43-L4-OR41, -NR43-L4-N(R42)2, -NR43-L4-SO2-R41, -NR43-L4-SO2-N(R42)2, -SO2-L4-OH, -SO2-L4-OR41, -SO2-L4-N(R42)2, -R44, -R45or -L4-R45group, provided that R4, including any optional substituents, contains no more than 8 carbon atoms;

[0407] R41is selected from a -R44or -R45group; each R42is independently selected from hydrogen or a -R44or -R45group, or any two R42may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0408] L4is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L4has a chain length of from 1 to 4 atoms, and wherein L4may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL4; each RL4is independently selected from a fluoro, methyl or fluoromethyl group; or any RL4and R41, or any RL4and any R42, may together with the atoms to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0409] R43is selected from hydrogen or a -R44group; each R44is independently selected from a C1-C4 alkyl, C3-C6 cycloalkyl or C4- Ce cycloalkylalkyl group, wherein the C1-C4 alkyl, C3-C6 cycloalkyl or C4-C6 cycloalkylalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R45is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe?, wherein any methyl group of R45may optionally be fluoro substituted;

[0410] R5is selected from hydrogen or a fluoro, chloro or bromo group;

[0411] R6is selected from a -R60or -OR60group;

[0412] R60is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0413] R7is selected from hydrogen or a -CN, -COOH, -COOR71, -CO-N(R72)2, -L7-COOH, -L7-COOR71, -L7-CO-N(R72)2, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, provided that R7, including any optional substituents, contains no more than 8 carbon atoms, and that the atom of R7that is directly attached to the reminder of the molecule is a carbon or hydrogen atom;

[0414] R71is selected from a -R73or -R74group; each R72is independently selected from hydrogen or a -R73or -R74group, or any two R72may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;

[0415] L7is a straight-chained alkylene or alkenylene group, wherein the straight- chained alkylene or alkenylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL7; each RL7is independently selected from a fluoro, methyl or fluoromethyl group; or any two RL7may, together with the atom or atoms to which they are attached, form a 3- to 6-membered monocyclic group, wherein the 3- to 6- membered monocyclic group is saturated or monounsaturated, and wherein the 3- to 6-membered monocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; or any RL7and R71, or any RL7and any R72, may together with the atoms of the -L7-COOR71, -L7-CO-N(R72)2, -L7-OR71or -L7-N(R72)2 group to which they are attached, form a 3- to 6-membered monocyclic heterocyclic group, wherein the 3- to 6-membered monocyclic heterocyclic group is saturated or monounsaturated, and wherein the 3- to 6-membered monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; each R73is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4-C6 cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group, wherein the C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4- Ce cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R74is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe2, wherein any methyl group of R74may optionally be fluoro substituted;

[0416] R8is selected from a hydrogen or a methyl or fluoromethyl group; or R7and R8together form a group -L78-, wherein -L78- is selected from a -CH2-CH2-, -CH2-CH2-CH2-, -CH2-NH-CH2-, -CH2-O-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-O-CH2-, -CH2-NH-CH2-CH2- or -CH2-O-CH2-CH2- group, wherein -L78- may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from an oxo (=0), -CN, methyl (Me), -OH, -OMe, -NH2, -NHMe or -NMe2 group, and wherein any methyl group of a -L78- substituent may optionally be fluoro substituted;

[0417] R9is hydrogen; each R14and R15is independently selected from hydrogen or a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group, or R14and R15together with the carbon atom to which they are attached may form a cyclopropyl or a cyclobutyl group, wherein the cyclopropyl or cyclobutyl group may optionally be substituted with one or more fluoro groups;

[0418] R16is selected from hydrogen or a fluoro, -R160, -CN, -CHO, -COR160, -CO2H or -CO2R160group, wherein R160is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group; and

[0419] R17is selected from hydrogen or a fluoro, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 5-membered saturated monocyclic group wherein the saturated monocyclic group may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from oxo (=0) or a methyl or fluoromethyl group;

[0420] L is selected from a bond, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group, or the two RLmay together with the carbon atom to which they are attached form a cyclopropyl group, wherein the cyclopropyl group may optionally be fluoro substituted; and

[0421] R10is a 5- to 10-membered aryl or heteroaryl group, wherein the aryl or the heteroaryl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two non-halo substituents each independently selected from an -OH, -SH, -NH2, -CN, or a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight- chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton.

[0422] In one aspect of the fourth exemplary embodiment:

[0423] R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)2, -SO2-R41, -SO2-N(R42)2, -L4-OH, -L4-OR41, -L4-N(R42)2, -L4-SO2-R41, -L4-SO2-N(R42)2, -O-L4-OH, -O-L4-OR41, -O-L4-N(R42)2, -O-L4-SO2-R41, -O-L4-SO2-N(R42)2, -NR43-L4-OH, -NR43-L4-OR41, -NR43-L4-N(R42)2, -NR43-L4-SO2-R41, -NR43-L4-SO2-N(R42)2, -R44, -R45or -L4-R45group, provided that R4, including any optional substituents, contains no more than 8 carbon atoms;

[0424] R41is selected from a -R44or -R45group; each R42is independently selected from hydrogen or a -R44or -R45group, or any two R42may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each RL4is independently selected from a fluoro, methyl or fluoromethyl group; or any RL4and R41, or any RL4and any R42, may together with the atoms to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R44is independently selected from a C1-C4 alkyl or C3-C6 cycloalkyl group, wherein the C1-C4 alkyl or C3-C6 cycloalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups;

[0425] R7is selected from hydrogen or a -CN, -COOH, -COOR71, -L7-COOH, -L7-COOR71, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, provided that R7, including any optional substituents, contains no more than 8 carbon atoms, and that the atom of R7that is directly attached to the reminder of the molecule is a carbon or hydrogen atom;

[0426] R71is selected from a -R73or -R74group; each R72is independently selected from hydrogen or a -R73or -R74group, or any two R72may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups;

[0427] L7is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL7; each RL7is independently selected from a fluoro, methyl or fluoromethyl group; or any RL7and R71, or any RL7and any R72, may together with the atoms of the -L7-COOR71, -L7-OR71or -L7-N(R72)2 group to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R73is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or Cs-Ce cycloalkenyl group, wherein the C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or Cs-Ce cycloalkenyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and

[0428] R8is selected from a hydrogen or a methyl or fluoromethyl group; or R7and R8together form a group -L78-, wherein -L78- is selected from a -CH2-CH2-, -CH2-CH2-CH2-, -CH2-NH-CH2-, -CH2-O-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-O-CH2-, -CH2-NH-CH2-CH2- or -CH2-O-CH2-CH2- group, wherein -L78- may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from an oxo (=0), -CN, methyl (Me), -OH, -OMe, -NH2, -NHMe or -NMe2 group, and wherein any methyl group of a -L78- substituent may optionally be fluoro substituted.

[0429] In a fifth exemplary embodiment, there is provided a compound of Formula (I) as defined above, wherein :

[0430] R1is hydrogen;

[0431] R2is hydrogen or a methyl or fluoromethyl group;

[0432] R3is selected from hydrogen or a fluoro, chloro or bromo -CN or methyl group, wherein the methyl group may optionally be fluoro substituted;

[0433] R4is selected from a fluoro, chloro, bromo, -R44, -OR44or -SO2-R44group;

[0434] R44is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0435] R5is hydrogen;

[0436] R6is a methyl or a fluoromethyl group;

[0437] R7and R8are each independently selected from hydrogen or a methyl or fluoromethyl group;

[0438] R9is hydrogen;

[0439] L10is selected from a bond or a -CH2- group; and

[0440] R10is a phenyl or 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group is optionally substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two non-halo substituents each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0441] Typically in accordance with the fifth exemplary embodiment:

[0442] R2is hydrogen;

[0443] R3, if present, is hydrogen; R4is selected from a -OR44or -SO2-R44group;

[0444] R44is selected from a methyl or fluoromethyl group; and

[0445] R10is an unsubstituted 5- or 6-membered heteroaryl group, or R10is a substituted phenyl or 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group is substituted with at least one -CN, fluoromethyl or fluoromethoxy group, and wherein the phenyl or the 5- or 6- membered heteroaryl group is optionally further substituted with a single Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0446] In one aspect of the fifth exemplary embodiment, Q3is N, i.e. the compound has the formula (lb) as defined above.

[0447] In another aspect of the fifth exemplary embodiment, Q3is C-R3, i.e. the compound has the formula (la) as defined above.

[0448] In a corresponding sixth exemplary embodiment, there is provided a compound of Formula (II) as defined above, wherein:

[0449] R1is hydrogen;

[0450] R4is selected from a fluoro, chloro, bromo, -R44, -OR44or -SO2-R44group;

[0451] R44is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0452] R5is hydrogen;

[0453] R6is a methyl or a fluoromethyl group;

[0454] R7and R8are each independently selected from hydrogen or a methyl or fluoromethyl group;

[0455] R9is hydrogen;

[0456] L10is selected from a bond or a -CH2- group;

[0457] R10is a phenyl or 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group is optionally substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two non-halo substituents each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with a single oxo (=0) group, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; each R14and R15is independently selected from hydrogen or a methyl or fluoromethyl group; and each R16and R17is independently selected from hydrogen or a methyl or fluoromethyl group.

[0458] Typically in accordance with the sixth exemplary embodiment:

[0459] R4is selected from a -OR44or -SO2-R44group;

[0460] R44is selected from a methyl or fluoromethyl group;

[0461] R10is an unsubstituted 5- or 6-membered heteroaryl group, or R10is a substituted phenyl or 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group is substituted with at least one -CN, fluoromethyl or fluoromethoxy group, and wherein the phenyl or the 5- or 6- membered heteroaryl group is optionally further substituted with a single Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton;

[0462] R14and R15are both hydrogen; and

[0463] R16and R17are both hydrogen.

[0464] In a seventh exemplary embodiment, there is provided a compound of Formula (III) as defined above, wherein:

[0465] R1is hydrogen;

[0466] R2is hydrogen;

[0467] R3is selected from hydrogen or a fluoro, chloro or bromo group;

[0468] R4is selected from a fluoro, chloro, bromo, -R44, -OR44or -SO2-R44group;

[0469] R44is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0470] R5is hydrogen;

[0471] R6is a methyl or a fluoromethyl group;

[0472] R7and R8are each independently selected from hydrogen or a methyl or fluoromethyl group; R9is hydrogen;

[0473] L10is selected from a bond or a -CH2- group;

[0474] X2is selected from N, C-H, C-Hal and C-RX2;

[0475] X3is selected from N, C-H, C-Hal and C-RX3;

[0476] X4is selected from N, C-H, C-Hal and C-RX4;

[0477] X5is selected from N, C-H, C-Hal and C-RX5; and

[0478] X6is selected from N, C-H, C-Hal and C-RX6; provided that no more than two of X2, X3, X4, X5and X6are N, and that at least three of X2, X3, X4, X5and X6are selected from N, C-H and C-Hal; each Hal is independently selected from F, Cl and Br; and

[0479] RX2, RX3, RX4, RX5and RX6are each independently selected from a -CN or a Ci-C6saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0480] In one aspect of the seventh exemplary embodiment, Q3is C-R3, i.e. the compound has the Formula (Illa) as defined above.

[0481] In one embodiment of such an aspect, RX2, RX3, RX4, RX5and RX6are each independently selected from a -CN or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0482] In another aspect of the seventh exemplary embodiment, Q3is N, i.e. the compound has the Formula (Illb) as defined above.

[0483] Typically in accordance with any aspect of the seventh exemplary embodiment:

[0484] R3, if present, is hydrogen;

[0485] R4is selected from a -OR44or -SO2-R44group;

[0486] R44is selected from a methyl or fluoromethyl group;

[0487] X2is selected from N, C-H and C-RX2;

[0488] X3is selected from N, C-H and C-RX3; X4is selected from N, C-H and C-RX4;

[0489] X5is selected from N, C-H and C-RX5; and

[0490] X6is selected from N, C-H and C-RX6; provided that no more than two of X2, X3, X4, X5and X6are N, and that at least three of X2, X3, X4, X5and X6are selected from N and C-H.

[0491] In one aspect of the seventh exemplary embodiment:

[0492] R3, if present, is hydrogen;

[0493] R4is selected from a -OR44or -SO2-R44group;

[0494] R44is selected from a methyl or fluoromethyl group;

[0495] X2is selected from N and C-H;

[0496] X3is selected from N and C-H;

[0497] X4is selected from N and C-H;

[0498] X5is selected from N and C-H; and

[0499] X6is selected from N and C-H; provided that two of X2, X3, X4, X5and X6are N and that three of X2, X3, X4, X5and X6are C-H.

[0500] Typically in such an aspect, L10is a bond, X3is N and X6is N.

[0501] In another aspect of the seventh exemplary embodiment:

[0502] R3, if present, is hydrogen;

[0503] R4is selected from a -OR44or -SO2-R44group;

[0504] R44is selected from a methyl or fluoromethyl group;

[0505] X2is C-H, C-Hal or C-RX2;

[0506] RX2is a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; one of X3and X4is C-CN, -C-RFor -C-ORF, wherein RFis a fluoromethyl group; and each remaining X3, X4, X5and X6is independently selected from N, C-H and C-Hal, provided that no more than two of X3, X4, X5and X6are N.

[0507] Typically in such an aspect: L10is a bond;

[0508] RX2is a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group includes one or two heteroatoms each independently selected from N and O in its carbon skeleton;

[0509] X3is C-CN, -C-RFor -C-ORF; and

[0510] X4, X5and X6are each independently selected from N, C-H and C-Hal, provided that no more than one of X4, X5and X6is N.

[0511] In a corresponding eighth exemplary embodiment, there is provided a compound of

[0512] Formula (IV) as defined above, wherein :

[0513] R1is hydrogen;

[0514] R4is selected from a fluoro, chloro, bromo, -R44, -OR44or -SO2-R44group;

[0515] R44is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0516] R5is hydrogen;

[0517] R6is a methyl or a fluoromethyl group;

[0518] R7and R8are each independently selected from hydrogen or a methyl or fluoromethyl group;

[0519] R9is hydrogen;

[0520] R14and R15are both hydrogen;

[0521] R16and R17are both hydrogen;

[0522] L10is selected from a bond or a -CH2- group;

[0523] X2is selected from N, C-H, C-Hal and C-RX2;

[0524] X3is selected from N, C-H, C-Hal and C-RX3;

[0525] X4is selected from N, C-H, C-Hal and C-RX4;

[0526] X5is selected from N, C-H, C-Hal and C-RX5; and

[0527] X6is selected from N, C-H, C-Hal and C-RX6; provided that no more than two of X2, X3, X4, X5and X6are N, and that at least three of X2, X3, X4, X5and X6are selected from N, C-H and C-Hal; each Hal is independently selected from F, Cl and Br; and

[0528] RX2, RX3, RX4, RX5and RX6are each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0529] In one aspect of the eighth exemplary embodiment, RX2, RX3, RX4, RX5and RX6are each independently selected from a -CN or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0530] Typically in accordance with any aspect of the eighth exemplary embodiment:

[0531] R4is selected from a -OR44or -SO2-R44group;

[0532] R44is selected from a methyl or fluoromethyl group;

[0533] X2is selected from N, C-H and C-RX2;

[0534] X3is selected from N, C-H and C-RX3;

[0535] X4is selected from N, C-H and C-RX4;

[0536] X5is selected from N, C-H and C-RX5; and

[0537] X6is selected from N, C-H and C-RX6; provided that no more than two of X2, X3, X4, X5and X6are N, and that at least three of X2, X3, X4, X5and X6are selected from N and C-H.

[0538] In one aspect of the eighth exemplary embodiment:

[0539] R4is selected from a -OR44or -SO2-R44group;

[0540] R44is selected from a methyl or fluoromethyl group;

[0541] X2is selected from N and C-H;

[0542] X3is selected from N and C-H;

[0543] X4is selected from N and C-H;

[0544] X5is selected from N and C-H; and

[0545] X6is selected from N and C-H; provided that two of X2, X3, X4, X5and X6are N and that three of X2, X3, X4, X5and X6are C-H.

[0546] Typically in such an aspect, L10is a bond, X3is N and X6is N.

[0547] In another aspect of the eighth exemplary embodiment:

[0548] R4is selected from a -OR44or -SO2-R44group; R44is selected from a methyl or fluoromethyl group;

[0549] X2is C-H, C-Hal or C-RX2;

[0550] RX2is a Ci-C6saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; one of X3and X4is C-CN, -C-RFor -C-ORF, wherein RFis a fluoromethyl group; and each remaining X3, X4, X5and X6is independently selected from N, C-H and C-Hal, provided that no more than two of X3, X4, X5and X6are N.

[0551] Typically in such an aspect:

[0552] L10is a bond;

[0553] RX2is a Ci-C6saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group includes one or two heteroatoms each independently selected from N and O in its carbon skeleton;

[0554] X3is C-CN, -C-RFor -C-ORF; and

[0555] X4, X5and X6are each independently selected from N, C-H and C-Hal, provided that no more than one of X4, X5and X6is N.

[0556] In a ninth exemplary embodiment, there is provided a compound of Formula (V) as defined above, wherein :

[0557] R1is hydrogen;

[0558] R2is hydrogen;

[0559] R3is selected from hydrogen or a fluoro, chloro or bromo group;

[0560] R4is selected from a fluoro, chloro, bromo, -R44, -OR44or -SO2-R44group;

[0561] R44is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0562] R5is hydrogen;

[0563] R6is a methyl or a fluoromethyl group;

[0564] R7and R8are each independently selected from hydrogen or a methyl or fluoromethyl group; R9is hydrogen;

[0565] L10is a bond;

[0566] A1is selected from N or C;

[0567] A2is selected from N, O, S, N-H, C-H, C-Hal, N-RN2and C-RA2;

[0568] A3is selected from N, O, S, N-H, C-H, C-Hal, N-RN3and C-RA3;

[0569] A4is selected from N, O, S, N-H, C-H, C-Hal, N-RN4and C-RA4; and

[0570] A5is selected from N, O, S, N-H, C-H, C-Hal, N-RN5and C-RA5; such that A1, A2, A3, A4and A5together form a 5-membered aromatic ring containing at least two ring carbon atoms; provided that at least two of A2, A3, A4and A5are selected from N, O, S, N-H, C-H and C-Hal; each Hal is independently selected from F, Cl and Br;

[0571] RN2, RN3, RN4and RN5are each independently selected from a C1-C4 alkyl, C3- C4 cycloalkyl, cyclopropylmethyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group; and

[0572] RA2, RA3, RA4and RA5are each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0573] In one aspect of the ninth exemplary embodiment, Q3is C-R3, i.e. the compound has the Formula (Va) as defined above.

[0574] In one embodiment of such an aspect:

[0575] RN2, RN3, RN4and RN5are each independently selected from a C1-C4 alkyl, C3- C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group; and

[0576] RA2, RA3, RA4and RA5are each independently selected from a -CN or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0577] In another aspect of the ninth exemplary embodiment, Q3is N, i.e. the compound has the Formula (Vb) as defined above. Typically in accordance with any aspect of the ninth exemplary embodiment:

[0578] R3, if present, is hydrogen;

[0579] R4is selected from a -OR44or -SO2-R44group;

[0580] R44is selected from a methyl or fluoromethyl group;

[0581] A1is C;

[0582] A2is O, S, N-H or N-RN2;

[0583] A3is C-CN;

[0584] A4is C-H;

[0585] A5is C-H; and

[0586] RN2is a methyl or fluoromethyl group.

[0587] In a corresponding tenth exemplary embodiment, there is provided a compound of

[0588] Formula (VI) as defined above, wherein :

[0589] R1is hydrogen;

[0590] R4is selected from a fluoro, chloro, bromo, -R44, -OR44or -SO2-R44group;

[0591] R44is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group;

[0592] R5is hydrogen;

[0593] R6is a methyl or a fluoromethyl group;

[0594] R7and R8are each independently selected from hydrogen or a methyl or fluoromethyl group;

[0595] R9is hydrogen;

[0596] R14and R15are both hydrogen;

[0597] R16and R17are both hydrogen;

[0598] L10is a bond;

[0599] A1is selected from N or C;

[0600] A2is selected from N, O, S, N-H, C-H, C-Hal, N-RN2and C-RA2;

[0601] A3is selected from N, O, S, N-H, C-H, C-Hal, N-RN3and C-RA3;

[0602] A4is selected from N, O, S, N-H, C-H, C-Hal, N-RN4and C-RA4; and

[0603] A5is selected from N, O, S, N-H, C-H, C-Hal, N-RN5and C-RA5; such that A1, A2, A3, A4and A5together form a 5-membered aromatic ring containing at least two ring carbon atoms; provided that at least two of A2, A3, A4and A5are selected from N, O, S, N-H, C-H and C-Hal; each Hal is independently selected from F, Cl and Br; RN2, RN3, RN4and RN5are each independently selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group; and

[0604] RA2, RA3, RA4and RA5are each independently selected from a -CN or a Ci-Ce saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0605] In one aspect of the tenth exemplary embodiment:

[0606] RN2, RN3, RN4and RN5are each independently selected from a C1-C4 alkyl, C3- C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group; and

[0607] RA2, RA3, RA4and RA5are each independently selected from a -CN or a C1-C4 saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups, and wherein the saturated hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton.

[0608] Typically in accordance with any aspect of the tenth exemplary embodiment:

[0609] R4is selected from a -OR44or -SO2-R44group;

[0610] R44is selected from a methyl or fluoromethyl group;

[0611] A1is C;

[0612] A2is O, S, N-H or N-RN2;

[0613] A3is C-CN;

[0614] A4is C-H;

[0615] A5is C-H; and

[0616] RN2is a methyl or fluoromethyl group.

[0617] In one aspect of any of the above embodiments, the compound of formula (I) or formula (II) has a molecular weight of from 228 to 750 Da. Typically, the compound of formula (I) or formula (II) has a molecular weight of from 250 to 500 Da. More typically, the compound of formula (I) or formula (II) has a molecular weight of from 280 to 450 Da. A third aspect of the invention provides a compound selected from the group consisting of:

[0618] A fourth aspect of the invention provides a pharmaceutically acceptable salt and / or solvate and / or prodrug of any compound of the first, second or third aspect of the invention.

[0619] In one embodiment, the fourth aspect of the invention provides a pharmaceutically acceptable salt and / or solvate of any compound of the first, second or third aspect of the invention. For example, the fourth aspect of the invention may provide (i) a pharmaceutically acceptable salt of any compound of the first, second or third aspect of the invention, or (ii) a pharmaceutically acceptable solvate of any compound of the first, second or third aspect of the invention, or (iii) a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of any compound of the first, second or third aspect of the invention.

[0620] The compounds of the present invention can be used both, in their free base form and their acid addition salt form. For the purposes of this invention, a "salt" of a compound of the present invention includes an acid addition salt. Acid addition salts are preferably pharmaceutically acceptable, non-toxic addition salts with suitable acids, including but not limited to inorganic acids such as hydrohalogenic acids (for example, hydrofluoric, hydrochloric, hydrobromic or hydroiodic acid) or other inorganic acids (for example, nitric, perchloric, sulfuric or phosphoric acid); or organic acids such as organic carboxylic acids (for example, propionic, butyric, glycolic, lactic, mandelic, citric, acetic, benzoic, salicylic, succinic, malic or hydroxysuccinic, tartaric, fumaric, maleic, hydroxymaleic, mucic or galactaric, gluconic, pantothenic or pamoic acid), organic sulfonic acids (for example, methanesulfonic, trifluoromethanesulfonic, ethanesulfonic, 2- hydroxyethanesulfonic, benzenesulfonic, toluene-p-sulfonic, naphthalene-2-sulfonic or camphorsulfonic acid) or amino acids (for example, ornithinic, glutamic or aspartic acid). The acid addition salt may be a mono-, di-, tri- or multi-acid addition salt. A preferred salt is a hydrohalogenic, sulfuric, phosphoric or organic acid addition salt. A preferred salt is a hydrochloric acid addition salt.

[0621] Where a compound of the invention includes a quaternary ammonium group, typically the compound is used in its salt form. The counter ion to the quaternary ammonium group may be any pharmaceutically acceptable, non-toxic counter ion. Examples of suitable counter ions include the conjugate bases of the protic acids discussed above in relation to acid addition salts.

[0622] The compounds of the present invention can also be used both, in their free acid form and their salt form. For the purposes of this invention, a "salt" of a compound of the present invention includes one formed between a protic acid functionality (such as a carboxylic acid group) of a compound of the present invention and a suitable cation. Suitable cations include, but are not limited to lithium, sodium, potassium, magnesium, calcium and ammonium. The salt may be a mono-, di-, trior multi-salt. Preferably the salt is a mono- or di-lithium, sodium, potassium, magnesium, calcium or ammonium salt. More preferably the salt is a mono-sodium salt or a mono-potassium salt.

[0623] Preferably any salt is a pharmaceutically acceptable non-toxic salt. However, in addition to pharmaceutically acceptable salts, other salts are included in the present invention, since they have potential to serve as intermediates in the purification or preparation of other, for example, pharmaceutically acceptable salts, or are useful for identification, characterisation or purification of the free acid or base.

[0624] The compounds and / or salts of the present invention may be anhydrous or in the form of a hydrate (e.g. a hemihydrate, monohydrate, dihydrate or trihydrate) or other solvate. Such other solvates may be formed with common organic solvents, including but not limited to, alcoholic solvents e.g. methanol, ethanol or isopropanol.

[0625] In one embodiment, the fourth aspect of the invention provides a prodrug of any compound of the first, second or third aspect of the invention. Similarly, the fourth aspect of the invention may provide a pharmaceutically acceptable salt and / or solvate of such a prodrug. For example, the fourth aspect of the invention may provide (i) a pharmaceutically acceptable salt of a prodrug, or (ii) a pharmaceutically acceptable solvate of a prodrug, or (iii) a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a prodrug.

[0626] In some embodiments of the present invention, therapeutically inactive prodrugs are provided. Prodrugs are compounds which, when administered to a subject such as a human, are converted in whole or in part to a compound of the invention. In most embodiments, the prodrugs are pharmacologically inert chemical derivatives that can be converted in vivo to the active drug molecules to exert a therapeutic effect. Any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, or stability of the compound or to otherwise alter the properties of the compound. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include, but are not limited to, compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, and / or dephosphorylated to produce the active compound. The present invention also encompasses salts and solvates of such prodrugs as described above.

[0627] The compounds, salts, solvates and prodrugs of the present invention may be obtained in all grades of purity, for example via conventional techniques such as recrystallisation and / or column chromatography.

[0628] For example, the compounds, salts, solvates and prodrugs of the present invention may be at least 90% pure, at least 95% pure, at least 99% pure, at least 99.5% pure or at least 99.9% pure, as measured by HPLC.

[0629] Alternately, the compounds, salts, solvates and prodrugs of the present invention may be at least 90% pure, at least 95% pure, at least 99% pure, at least 99.5% pure or at least 99.9% pure, as measured by LCMS.

[0630] Alternately still, the compounds, salts, solvates and prodrugs of the present invention may be at least 90% pure, at least 95% pure, at least 99% pure, at least 99.5% pure or at least 99.9% pure, as measured by1H NMR. The compounds, salts, solvates and prodrugs of the present invention may contain at least one chiral centre. The compounds, salts, solvates and prodrugs may therefore exist in at least two isomeric forms. The present invention encompasses racemic mixtures of the compounds, salts, solvates and prodrugs of the present invention as well as enantiomerically enriched and substantially enantiomerically pure isomers. For the purposes of this invention, a "substantially enantiomerically pure" isomer of a compound comprises less than 5% of other isomers of the same compound, more typically less than 2%, and most typically less than 0.5% by weight.

[0631] The compounds, salts, solvates and prodrugs of the present invention may contain any stable isotope including, but not limited to12C,13C,1H,2H (D),14N,15N,16O,17O,18O,19F and127I, and any radioisotope including, but not limited tonC,14C,3H (T),13N,15O,18F,123I,124I,125I and131I.

[0632] The compounds, salts, solvates and prodrugs of the present invention may be in any polymorphic or amorphous form.

[0633] A fifth aspect of the invention provides a pharmaceutical composition comprising a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt and / or solvate and / or prodrug of the fourth aspect of the invention, and a pharmaceutically acceptable excipient.

[0634] Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Aulton's Pharmaceutics - The Design and Manufacture of Medicines", M. E. Aulton and K. M. G. Taylor, Churchill Livingstone Elsevier, 4thEd., 2013.

[0635] Pharmaceutically acceptable excipients including adjuvants, diluents or carriers that may be used in the pharmaceutical compositions of the invention are those conventionally employed in the field of pharmaceutical formulation, and include, but are not limited to, sugars, sugar alcohols, starches, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycerine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0636] A sixth aspect of the invention provides a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect of the invention, or a pharmaceutical composition of the fifth aspect of the invention, for use in medicine, and / or for use in the treatment or prevention of a disease, disorder or condition. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to a subject.

[0637] The term "treatment" as used herein refers equally to curative therapy, and ameliorating or palliative therapy. The term includes obtaining beneficial or desired physiological results, which may or may not be established clinically. Beneficial or desired clinical results include, but are not limited to, the alleviation of symptoms, the prevention of symptoms, the diminishment of extent of disease, the stabilisation (i.e., not worsening) of a condition, the delay or slowing of progression / worsening of a condition / symptom, the amelioration or palliation of a condition / symptom, and remission (whether partial or total), whether detectable or undetectable. The term "palliation", and variations thereof, as used herein, means that the extent and / or undesirable manifestations of a physiological condition or symptom are lessened and / or time course of the progression is slowed or lengthened, as compared to not administering a compound, salt, solvate, prodrug or pharmaceutical composition of the present invention. The term "prevention" as used herein in relation to a disease, disorder or condition, relates to prophylactic or preventative therapy, as well as therapy to reduce the risk of developing the disease, disorder or condition. The term "prevention" includes both the avoidance of occurrence of the disease, disorder or condition, and the delay in onset of the disease, disorder or condition. Any statistically significant (p < 0.05) avoidance of occurrence, delay in onset or reduction in risk as measured by a controlled clinical trial may be deemed a prevention of the disease, disorder or condition. Subjects amenable to prevention include those at heightened risk of a disease, disorder or condition as identified by genetic or biochemical markers. Typically, the genetic or biochemical markers are appropriate to the disease, disorder or condition under consideration and may include for example, inflammatory biomarkers such as C- reactive protein (CRP) and monocyte chemoattractant protein 1 (MCP-1) in the case - I ll - of inflammation, as well as biomarkers associated with the complement system, such as C5a, terminal complement complex, Factor B, fragments Ba and Bb, Complement C3 fragments C3a and C3b, and downstream degradation products iC3b, C3c and C3d(g).

[0638] A seventh aspect of the invention provides the use of a compound of the first, second or third aspect, or a pharmaceutically effective salt, solvate or prodrug of the fourth aspect, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition. Typically, the treatment or prevention comprises the administration of the compound, salt, solvate, prodrug or medicament to a subject.

[0639] An eighth aspect of the invention provides a method of treatment or prevention of a disease, disorder or condition, the method comprising the step of administering an effective amount of a compound of the first, second or third aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect, or a pharmaceutical composition of the fifth aspect, to thereby treat or prevent the disease, disorder or condition. Typically, the administration is to a subject in need thereof.

[0640] Dysregulation of the alternative complement pathway due to genetics or the presence of autoantibodies can lead to many different diseases. Common polymorphisms in complement proteins or rare mutations can cause dysfunction or dysregulation of the complement system due to over-activation or underregulation. Autoantibodies can bind to self-cells and drive the complement system such that the capacity of the natural regulators to protect is overwhelmed. In some cases, the cells' natural defence mechanism, such as shedding of active complexes, can cause symptoms due to loss of critical molecules from the cell surface, such as the acetylcholine receptor. In many diseases, however, the complement system is not the primary trigger of disease but acts secondarily to other disease-causing triggers to set up a vicious cycle of inflammation that is propagated by the complement system. In these diseases, inhibition of the complement system can bring about a treatment effect.

[0641] In some instances, gain of function Complement C3 and / or Factor B mutations, and / or the loss of function in the regulatory proteins eventuate in uncontrolled C3 activation (Garred, P., Tenner, A. J., and Mollnes, T. E. Pharmacol. Rev. 2021, 73, 792-827). In some cases, common polymorphisms or rare mutations can lead to distinctive phenotypes due to specific impact on function, such as the ability to bind membranes. Some genetic changes result in proteins with altered ability to bind to certain structures (such as glycosaminoglycans or disease-associated epitopes), resulting in tissue-specific diseases. The domain in which the mutation or polymorphism resides can impact disease phenotype.

[0642] Accordingly, a ninth aspect of the invention provides a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect of the invention, or a pharmaceutical composition of the fifth aspect of the invention, for use in the treatment or prevention of a disease, disorder or condition in an individual, wherein the individual has a germline or somatic mutation in Complement C3 or Factor B, or a germline or somatic mutation in a regulator of the alternative pathway, or a germline or somatic mutation in an enzyme that directly or indirectly causes the production or activation of Factor B. The mutation may be, for example, a gain-of- function or other mutation of Factor B resulting in increased Factor B or C3 / C5 convertase activity. Alternately, the mutation may be a gain-of-function or other mutation of Complement C3 resulting in increased Factor B or C3 / C5 convertase activity. Similarly, the mutation may be a loss of function in a negative regulator (such as Factor H) resulting in increased alternative pathway activity, a gain of function in a positive regulator (such as properdin) resulting in increased alternative pathway activity, or a gain of function in an enzyme that causes the production or activation of Factor B. Such mutations are discussed in Rodriguez de Cordoba, Immunological Reviews, 2023, 313, 71-90, and Kouser et al., Front. Immunol., 2013, 4(93), 1-12. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to the individual. The use may also comprise the diagnosis of an individual having a germline or somatic mutation in (i) Complement C3, (ii) Factor B, (iii) a regulator of the alternative pathway, or (iv) an enzyme that directly or indirectly causes the production or activation of Factor B, wherein the compound, salt, solvate, prodrug or pharmaceutical composition is administered to an individual on the basis of a positive diagnosis for the mutation. Typically, identification of the mutation in Complement C3, Factor B, the regulator or the enzyme in the individual may be by any suitable genetic or biochemical means. A tenth aspect of the invention provides the use of a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect of the invention, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition in an individual, wherein the individual has a germline or somatic mutation in Complement C3 or Factor B, or a germline or somatic mutation in a regulator of the alternative pathway, or a germline or somatic mutation in an enzyme that directly or indirectly causes the production or activation of Factor B. The mutation may be, for example, a gain-of-function or other mutation of Factor B resulting in increased Factor B or C3 / C5 convertase activity. Alternately, the mutation may be a gain-of-function or other mutation of Complement C3 resulting in increased Factor B or C3 / C5 convertase activity. Similarly, the mutation may be a loss of function in a negative regulator (such as Factor H) resulting in increased alternative pathway activity, a gain of function in a positive regulator (such as properdin) resulting in increased alternative pathway activity, or a gain of function in an enzyme that causes the production or activation of Factor B. Typically, the treatment or prevention comprises the administration of the compound, salt, solvate, prodrug or medicament to the individual. The treatment or prevention may also comprise the diagnosis of an individual having a germline or somatic mutation in (i) Complement C3, (ii) Factor B, (iii) a regulator of the alternative pathway, or (iv) an enzyme that directly or indirectly causes the production or activation of Factor B, wherein the compound, salt, solvate, prodrug or medicament is administered to an individual on the basis of a positive diagnosis for the mutation. Typically, identification of the mutation in Complement C3, Factor B, the regulator or the enzyme in the individual may be by any suitable genetic or biochemical means.

[0643] An eleventh aspect of the invention provides a method of treatment or prevention of a disease, disorder or condition, the method comprising the steps of diagnosing of an individual having a germline or somatic mutation in (i) Complement C3, (ii) Factor B, (iii) a regulator of the alternative pathway, or (iv) an enzyme that directly or indirectly causes the production or activation of Factor B, and administering an effective amount of a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect of the invention, or a pharmaceutical composition of the fifth aspect of the invention, to the positively diagnosed individual, to thereby treat or prevent the disease, disorder or condition. Typically, the administration is to a subject in need thereof. In general embodiments of any of the sixth to eleventh aspects of the invention, the disease, disorder or condition may be a disease, disorder or condition of the immune system, the cardiovascular system, the renal system, the respiratory system, the central nervous system, the reproductive system, the ocular system, the metabolic system, the haematological system, may be a cancer or other malignancy, and / or may be caused by or associated with a pathogen.

[0644] It will be appreciated that these general embodiments defined according to broad categories of diseases, disorders and conditions are not mutually exclusive. In this regard any particular disease, disorder or condition may be categorized according to more than one of the above general embodiments. A non-limiting example is type I diabetes which is an autoimmune disease and a disease of the endocrine system.

[0645] In one embodiment of the sixth, seventh, eighth, ninth, tenth or eleventh aspect of the invention, the disease, disorder or condition is responsive to Factor B inhibition. As used herein, the term "Factor B inhibition" refers to the complete or partial reduction in the level of activity of Factor B, either unbound or in complex with C3b / C3(H2O), and includes, for example, (i) the inhibition of active Factor B or Bb, (ii) the inhibition of latent Factor B (the zymogen) and / or (iii) the inhibition of the conversion of latent Factor B into active Factor B.

[0646] A number of ocular conditions have been shown to involve Factor B including, in particular, age-related macular degeneration (Schramm, E. C. et al, Mol. Immunol.

[0647] 2014, 61, 118-125), retinal detachment (Sweigard, J. H. et al, Sci. Transl. Med.

[0648] 2015, 7, 297rall6-297rall6), Doyne honeycomb retinal dystrophy, also known as malattia leventinese (DHRD / ML) (Crowley, M. A. et al, Hum. Mol. Genet. 2023, ddacl87), diabetic macular oedema and diabetic retinopathy (Murray, H. et al, Investig. Ophthalmol. Vis. Sci. 2018, 59, 5476-5476; Xu et al, Eur. J. Pharmacol. 2016,787, 94-104, Gerl et al, Invest. Opthalmol. Vis. Sci, 2002, 43(4), 1104-1108; Zhang et al, Diabetes 2002, 51(12), 3499-3504; and Murray 'Defining the Role of Complement Factor B of the Alternative Complement Pathway in Diabetic Retinopathy', PhD thesis, University of Sheffield, 2019), retinal ischemia reperfusion (Inafuku, S., Klokman, G., and Connor, K. M. Front. Mol. Neurosci. 2018, 11, 278), non-infectious uveitis (Yang, M. et al, Immunol. Res. 2016, 64, 610-618; Eskandarpour et al, Am. J. Pathol. 2021, 191(2), 320-334, and Tanaka et al, BMC Opthalmol. 2014, 14, 83), polypoidal choroidal neovascularization and ocular angiogenesis (Murray, H. et al, Int. J. Mol. Sci. 2021, 22, 9580).

[0649] Factor B has been linked to a number of respiratory conditions and lung diseases including those caused by SARS-CoV-2 (Yan, B. et al, Sci. Immunol. 2021, 6, eabg0833), Covid-19 (Fujimura, Y., and Holland, L. Z. Int. J. Hematol. 2022, 115, 457-469), smoke-induced mucosal damage (Davis, K. S. et al, Otolaryngol. Head Neck Surg. 2010, 143, 152-158), airway hyperresponsiveness allergic asthma (Herbert, C. et al, Clin. Sci. (Lond) 2017, 131, 499-509), idiopathic pulmonary fibrosis (Meliconi, R. et al, Clin. Immunol. Immunopathol. 1990, 57, 64-73), and airway hyperresponsiveness with inflammation (Taube, C. et al, Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 8084-8089).

[0650] Factor B has also been implicated in a number of central nervous system conditions including ischemic stroke (Turek-Jakubowska, A. et al, J. Clin. Med. 2022, 11, 339; and Elvington, A. et al, J. Immunol. 2012, 189(9), 4640-4647), traumatic brain injury (Lindblad, C. et al, Crit. Care 2021, 25, 103; Mallah, K. et al, Acta Neuropathol. Commun. 2021, 9(1), 72; and Alawieh, A. et al, J. Neurosci. 2018, 38(10), 2519-2532), spinal cord injury (Baldan-Martin, M. et al, Adv. Wound Care (New Rochelle) 2020, 9, 277-294; and Qiao, F. et al, Am. J. Pathol. 2010, 177(6), 3061-3070), Toxoplasma infection-induced neurological disorders (Shinjyo, N. et al, Front. Immunol. 2020, 11, 603924), prion diseases (Chen, C. et al, Med. Microbiol. Immunol. 2020, 209, 81-94; and Klein, M. A. et al, Mat. Med. 2001, 7(4), 488- 492), multiple sclerosis (Solmaz, I. et al, J. Neuroimmunol. 2020, 348, 577359; and Linzey, M. et al, Front. Immunol. 2022, 13, 924734), amyotrophic lateral sclerosis (Lee, J. D. et al, J. Neuroinflammation 2018, 15, 171), depression (Wang, Q. et al, Psychiatry Research 2019, 272, 404-410; and Reddy, P. V. et al, Clin. Psychopharmacol. Neurosci. 2023, 21(2), 313-319), pain (Wahlen, K. et al, Front. Psychol. 2018, 9, 2400), schizophrenia (Mayilyan, K. R., Weinberger, D. R., and Sim, R. B. Drug News Perspect. 2008, 21, 200; and Boyajyan, A. et al, Neurochemical Research 2010, 35, 894-898), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (Unlu, M. et al, Neurosci. Lett. 2000, 282, 149-152), lupus cerebritis (Alexander, J. J. et al, Eur. J. Immunol. 2007, 37, 1691-1701) and Alzheimer's disease (Morgan, A. R. et al, Alzheimers Dement. 2019, 15, 776-787; and Strohmeyer, R. et al, Brain Res. Mol. Brain Res. 2000, 81(1-2), 7-18). Several cardiovascular diseases have been shown to be associated with Factor B, including heart failure (Holt, M. F. et al, Front. Immunol. 2021, 12, 800978), cardiac remodelling (Yang, Y. et al, Eur. J. Immunol. 2020, 50, 220-233), aortic stenosis (Shahini, N. et al, J. Immunol. 2019, 203, 1973-1980), cardiometabolic disease (Coan, P. M. et al, Hypertension 2017, 70, 624-633) and cardiac ischemia and reperfusion (Chun, N. et al, PLOS ONE 2017, 12, e0179450).

[0651] Factor B has been suggested to play a role in a number of haematological and blood disorders, including idiopathic thrombocytopenic purpura (ITP) (Weitz, I. C. et al, Br. J. Haematol. 2023, 203(1), 96-100; and Shindo, R. et al, Immunol. Med. 2023, 1-9), paroxysmal nocturnal hemoglobinuria (PNH) (Brodsky, R. A. Blood 2014, 124, 2804-2811; and Schubart, A. et al, Proc. Natl. Acad. Sci. USA 2019, 116(6), 7926- 7931), atypical hemolytic uremic syndrome (Rodnguez de Cordoba, S. et al, Semin. Thromb. Hemost. 2014, 40, 422-430; and Goicoechea de Jorge, E. et al, Proc. Natl. Acad. Sci. USA 2007, 104(1), 240-245), transplant-associated thrombotic microangiopathy (Sartain, S. et al, Pediatr. Blood Cancer 2020, 67, e28070), vasoocclusive crises in sickle cell disease, and delayed hemolytic transfusion reactions (DHTR) in individuals suffering from sickle cell disease (Merle, N. S. et al, Transfus. Clin. Biol. 2019, 26(2), 116-124; and Chudwin, D. S. et al, Clin. Immunol. Immunopathol. 1994, 71(2), 199-202).

[0652] Factor B has been implicated in the pathogenesis of various cancers, including pancreatic cancer (Shimazaki, R. et al, Cell Oncol. 2021, 44, 937-950), photocarcinogenesis (Byrne, S. N. et al, Photochem. Photobiol. Sci. 2015, 14, 801- 806), breast cancer (Suman, S. et al, J. Proteomics 2016, 148, 183-193), gastro- oesophageal cancer (Wu, C. et al, Br. J. Cancer 2015, 113, 220-225), head and neck squamous carcinoma (Ohshiro, K. et al, Int. J. Oncol. 2007, 30, 743-749), and adenoma to carcinoma and cutaneous squamous cell carcinoma (Riihila, P. et al, Am. J. Pathol. 2017, 187, 1186-1197).

[0653] A number of renal diseases have been shown to be associated with Factor B (Wang, F. M. et al, Front. Genet. 2021, 12, 690952), including atypical hemolytic uremic syndrome as discussed above, IgA nephropathy (Zhou, X. J. et al, Clin. J. Am. Soc. Nephrol. 2021, 16, 213-224; Rizk, D. V. et al, Kidney Int. Rep. 2023, 8(5), 968- 979; Poppelaars, F. et al, J. Clin. Med. 2021, 10(20), 4715; and Daha, M. R. et al, J. Nephrol. 2016, 29(1), 1-4), membranous nephropathy including primary membranous nephropathy (Couser, W. G. Clin. J. Am. Soc. Nephrol. 2017, 12, 983- 997; and Novartis Investor Presentation, 'Iptacopan (LNP023) update' 22 June 2021), C3 glomerulopathy (C3G) including dense deposit disease and C3 glomerulonephritis (Barbour, T. D. et al, Nephrol. Dial. Transplant. 2013, 28, 1685- 1693; Zhang, Y. et al, Clin. J. Am. Soc. Nephrol. 2012, 7, 265-274; Pickering, M. C. et al, Kidney Int. 2013, 84(6), 1079-1089; Zanchi, C. et al, Mol. Immunol. 2023, 161, 25-32; Bomback, A. S. et al, Kidney Int. Rep. 2022, 7(10), 2150-2159; and Novartis Press Release 'Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G), 4 November 2021), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) (latropoulos, P. et al, J. A. Soc. Nephrol. 2018, 29(1), 283-294), thrombotic microangiopathy (TMA)-mediated acute kidney injury (AKI) (Guzzo, G. et al, BMC Nephrol. 2021, 22, 252), malignant nephrosclerosis (Zhang, Y. et al, Nephrol. Dial. Transplant. 2021, 36, 1222-1233), glomerular sclerosis (Zhang, Y. et al, J. Proteomics 2015, 123, 89-100), renal allograft (Jager, N. M. et al, Front. Immunol. 2019, 10, 2528), autosomal dominant polycystic kidney disease (Su, Z. et al, J. Intern. Med. 2014, 276, 470-485), acute kidney injury (Laskowski, J. et al, Am. J. Physiol. Renal Physiol. 2019, 317, F650-F657), focal segmental glomerulosclerosis (FSGS) (Lenderink, A. M. et al, Am. J. Physiol. Renal Physiol. 2007, 293(2), F555- F564; Peng, Y. et al, Front. Pediatr. 2023, 11, 1137375; and Turnberg, D. et al, J. Immunol. 2006, 177(6), 4094-4102) and postinfectious glomerulonephritis (Sethi, S. et al, Kidney Int., 2013, 83(2), 293-299).

[0654] Factor B has been suggested to have a role in a number of metabolic conditions, including diabetes related conditions including, in particular, gestational diabetes (Shen, Y. et al, Gynecol. Endocrinol. 2022, 38, 158-163), cardiometabolic disease (Coan, P. M. et al, Hypertension, 2017, 70, 624-633), diabetic macular oedema and diabetic retinopathy as discussed above, diabetic kidney disease (Lu, Q. et al, JCI Insight 2021, 6, el47716), and metabolic disorders including diet-induced steatosis and dyslipidemia (Sadana, P. et al, Int. J. Mol. Sci. 2020, 21, 7472).

[0655] Within the reproductive system, Factor B has been linked to infertility (Sim, Y. J., Ryu, A. R., and Lee, M. Y. Biotechnol. Appl. Biochem. 2022, 69, 289-295), inflammation during pregnancy (Livson, S. et al, Front. Immunol. 2022, 13, 925630), spontaneous preterm birth (Lynch, A. M. et al, Am. J. Obstet. Gynecol. 2008, 199, 354. el-8), pregnancy loss in antiphospholipid syndrome (Breen, K. A. et al, Thromb. Haemost. 2012, 107(3), 423-429; Salmon, J. E. et al, Lupus. 2012, 12(7), 535-538; and Salmon, J. E. et al, Curr. Dir. Autoimmun. 2004, 7, 133-148), and pre-eclampsia (Jia, K. et al, Med. Sci. Monit. 2019, 25, 7087-7093; Lynch, A. M. et al, Am. J. Obstet. Gynecol. 2008, 198(4), 385; and Blakey, H. et al, Pregnancy Hypertens. 2023, 32, 43-49).

[0656] Factor B has also been linked to several pathogenic diseases, including dengue- associated DHF (dengue hemorrhagic fever) and DSS (dengue shock syndrome) (Cabezas-Falcon, S. et al, J. Gen. Virol. 2021, 102, 001547; and Dalrymple, N. A. et al, J. Virol. 2012, 86(12), 6408-6415), hyper-inflammatory complications of severe sepsis (Li, D. et al, Crit. Care Med. 2016, 44, e289-299; and Zou, L. et al, J. Immunol. 2013, 191(11), 5625-5635), fulminant meningococcal septicemia (Brandtzaeg, P. et al, J. Infect. Dis. 1996, 173, 647-655), leprosy caused by Mycobacterium leprae (El Idrissi, N. B. et al, Clin. Exp. Immunol. 2016, 184(3), 338-346; and El Idrissi, N. B. et al, Acta Neuropathol. 2015, 129(5), 653-667), and postinfectious glomerulonephritis (Chauvet, S. et al, J. Am. Soc. Nephrol. 2020, 31, 829-840).

[0657] Other diseases, disorders or conditions in which Factor B has been implicated or shown to be involved include: liver diseases including chronic hepatitis B (Chen, H. et al, Aliment. Pharmacol. Ther. 2020, 51, 469-478; Seo, T. Y. et al, BMC Med. Genet. 2020, 21(1), 241; and Jiang, D-K. et al, Hepatology, 2015, 62(1), 118-128), acute alcohol-associated hepatitis (Fan, X. et al, Hepatology 2021, 73, 983- 997) and large duct biliary obstruction and viral hepatitis (Potter, B. J. et al, Digestion 1978, 18, 371-383); auto-immune conditions including cold agglutinin disease (Berentsen, S. Semin. Hematol. 2018, 55, 141-149), ANCA vasculitis (Xiao, H. et al, Am. J. Pathol. 2007, 170, 52-64), IgA vasculitis (Demir, S. et al, Diagnostics (Basel) 2023, 13(10), 1729), systemic lupus erythematosus including lupus nephritis (Kono, D. H., Theofilopoulos, A. N. (2011) Chapter 4 - Genetics of Lupus in Mice, in Systemic Lupus Erythematosus (Fifth Edition) (Lahita, R. G. ed.), Academic Press, San Diego; Chen, K. et al, Biomed. Pharmacother. 2022, 153, 113433; and Wilson, M. R. et al, Clin. Exp. Immunol. 1976, 26(1), 11-20), Sjogren's syndrome (Larssen, E. et al, SAGE Open Med. 2019, 7, 2050312119850390), myasthenia gravis (Sublas, M. et al, J. Immunology 2014, 193, 5567-5575), acquired thrombotic thrombocytopenic purpura (TTP) (Cao, W. et al, Haematologica 2016, 101, 1319-1326), neuromyelitis optica (Palace, J. et al, Clinical Trial 2021, 47, 102641), Guillian-Barre syndrome (Campbell, C. I. et al, Brain Commun. 2022, 4(6), fcac306l and Halstead, S. K. et al. Brain 2004, 127(9), 2109-2123); and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (Querol, L. et al, J. Peripher. Nerv. Syst., 2023, 28(2), 276-285); musculoskeletal disorders and muscle inflammation (Ghafouri, B. et al, BMC Musculoskelet. Disord. 2016, 17, 206; and Frenette, J. et al, Am. J. Pathol. 2000, 156, 2103-2110), rheumatoid arthritis (Krick, E. H. et al, Clin. Exp. Immunol. 1978, 34, 1-9; and Holers, V. M. et al, Front. Immunol., 2018, 9, 1057), and osteoarthritis (Assirelli, E. et al, Front. Immunol. 2020, 11, 535010); inflammatory bowel disease (Shi, D. et al, J. Hum. Genet. 2020, 65, 241- 249); primary varicose veins (Shadrina, A. et al, Gene 2018, 659, 93-99); antiphospholipid syndrome (Breen, K. A. et al, Thromb. Haemost. 2012, 107, 423-429; Kim, M. Y. et al, Ann. Rheum. Dis. 2018, 77(4), 549-555; and Picceli, V. F. et al, Lupus, 2016, 25(4), 412-417); bullous pemphigoid (Nelson, K. C. et al, J. Clin. Invest. 2006, 116, 2892- 2900); hemodialysis (Ekdahl, K. N. et al, Immunol. Rev. 2023, 313(1), 91-103); coeliac disease (da Rosa Utiyama, S. R. et al, Int. J. Immunogenet. 2005, 32, 307-314); burns (Wan, K. C. et al, Burns 1998, 24, 241-244); hidradenitis suppurativa and pyoderma gangraenosum (Giamarellos- Bourboulis, E. J. et al, Br. J. Dermatol. 2020, 183(1), 176-178); rhabdomyolysis (Boudhabhay, I. et al, Kidney Int. 2021, 99(3), 581-597); nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) (Segers, F. M. et al, PLoS One 2014, 9(10), ell0053; and Zhao et al, Front. Immunol. 2022, 13, 1054159);

[0658] Gaucher disease (Pandey, M. K. et al, Nature, 2017, 543(7643), 108-112; and Serfecz, J. C. et al, Int. J. Mol. Sci. 2021, 22(18), 9912); and acquired partial lipodystrophy (Misra, A. et al, Medicine (Baltimore), 2004, 83(1), 18-31, and Sissons, J. G. et al, New England Journal of Medicine, 1976, 294(9), 461-465).

[0659] Accordingly, any of the diseases, disorders or conditions listed above may be treated or prevented in accordance with the sixth, seventh, eighth, ninth, tenth or eleventh aspect of the present invention. Particular examples of diseases, disorders or conditions which may be responsive to Factor B inhibition and which may be treated or prevented in accordance with the sixth, seventh, eighth, ninth, tenth or eleventh aspect of the present invention include:

[0660] (i) ocular diseases, disorders or conditions, such as age-related macular degeneration, retinal detachment, Doyne honeycomb retinal dystrophy (also known as malattia leventinese) (DHRD / ML), retinal ischemia reperfusion, non-infectious uveitis, and diabetic retinopathy and diabetic macular oedema;

[0661] (ii) haematological diseases, disorders or conditions, such as cold agglutinin disease, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, transplant-associated thrombotic microangiopathy, vaso-occlusive crises in sickle cell disease, and delayed hemolytic transfusion reactions (DHTR) in individuals suffering from sickle cell disease;

[0662] (iii) renal diseases, disorders or conditions, such as IgA nephropathy, primary membranous nephropathy, C3 glomerulopathy (C3G) including dense deposit disease and glomerulonephritis, immune complex- mediated membranoproliferative glomerulonephritis (IC-MPGN), thrombotic microangiopathy (TMA)-mediated acute kidney injury (AKI), malignant nephrosclerosis, glomerular sclerosis, atypical hemolytic uremic syndrome, focal segmental glomerulosclerosis (FSGS), postinfectious glomerulonephritis, renal allograft, and acute kidney injury;

[0663] (iv) respiratory diseases, disorders or conditions, such as airway hyperresponsiveness with inflammation, idiopathic pulmonary fibrosis, and those associated with SARS-CoV-2;

[0664] (v) central nervous system diseases, disorders or conditions, such as Alzheimer's disease, multiple sclerosis, ischemic stroke, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, schizophrenia, and lupus cerebritis;

[0665] (vi) cardiovascular diseases, disorders or conditions, such as heart failure, cardiac remodelling, aortic stenosis, cardiometabolic disease and cardiac ischemia and reperfusion;

[0666] (vii) reproductive diseases, disorders or conditions, such as pre-eclampsia;

[0667] (viii) metabolic diseases, disorders or conditions, such as complications of type 2 diabetes including diabetic retinopathy and diabetic kidney disease; (ix) cancers such as pancreatic cancer, photocarcinogenesis and cutaneous squamous cell carcinoma;

[0668] (x) auto-immune diseases, disorders or conditions, such as cold agglutinin disease, ANCA associated vasculitis, systemic lupus erythematosus including lupus nephritis, myasthenia gravis, coeliac disease, neuromyelitis optica, Guillian-Barre syndrome and acquired thrombotic thrombocytopenic purpura (TTP);

[0669] (xi) musculoskeletal diseases, disorders or conditions, such as rheumatoid arthritis and osteoarthritis;

[0670] (xii) antiphospholipid syndrome;

[0671] (xiii) skin diseases, disorders or conditions, such as bullous pemphigoid;

[0672] (xiv) hemodialysis; and

[0673] (xv) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in Factor B.

[0674] More typically, the disease, disorder or condition is selected from :

[0675] (i) an ocular disease, disorder or condition;

[0676] (ii) a haematological disease, disorder or condition;

[0677] (iii) a renal disease, disorder or condition;

[0678] (iv) a cancer; or

[0679] (v) an auto-immune disease, disorder or condition.

[0680] In one embodiment, the disease, disorder or condition is a non-cancerous disease, disorder or condition. For example, the sixth aspect of the invention may provide a compound of Formula (lb), as defined above, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, for use in the treatment or prevention of a non-cancerous disease, disorder or condition. Similarly, the seventh aspect of the invention may provide the use of provide a compound of Formula (lb), as defined above, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a non- cancerous disease, disorder or condition. Likewise, the eighth aspect of the invention may provide a method of treatment or prevention of a disease, disorder or condition, the method comprising the step of administering an effective amount of a compound of Formula (lb), as defined above, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, to thereby treat or prevent the disease, disorder or condition. Typically where the disease, disorder or condition is non-cancerous, the disease, disorder or condition is not a pre-cancerous disease, disorder or condition. Typically, the non-cancerous disease, disorder or condition does not involve a tumorous growth. Typically, the non-cancerous disease, disorder or condition is responsive to Factor B inhibition. For example, the disease, disorder or condition may be a non-cancerous disease, disorder or condition selected from:

[0681] (i) an ocular disease, disorder or condition;

[0682] (ii) a haematological disease, disorder or condition;

[0683] (iii) a renal disease, disorder or condition;

[0684] (iv) a respiratory disease, disorder or condition;

[0685] (v) a central nervous system disease, disorder or condition;

[0686] (vi) a cardiovascular disease, disorder or condition;

[0687] (vii) a reproductive disease, disorder or condition;

[0688] (viii) a metabolic disease, disorder or condition;

[0689] (ix) an auto-immune disease, disorder or condition;

[0690] (x) a musculoskeletal disease, disorder or condition;

[0691] (xi) antiphospholipid syndrome;

[0692] (xii) a skin disease, disorder or condition;

[0693] (xiii) hemodialysis; or

[0694] (xiv) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in Factor B.

[0695] In one embodiment of the sixth, seventh, eighth, ninth, tenth or eleventh aspect of the invention, the disease, disorder or condition is selected from:

[0696] (i) acute kidney injury;

[0697] (ii) age-related macular degeneration;

[0698] (iii) airway hyperresponsiveness with inflammation;

[0699] (iv) Alzheimer's disease;

[0700] (v) amyotrophic lateral sclerosis;

[0701] (vi) ANCA vasculitis;

[0702] (vii) antiphospholipid syndrome;

[0703] (viii) aortic stenosis;

[0704] (ix) atypical hemolytic uremic syndrome;

[0705] (x) acquired partial lipodystrophy;

[0706] (xi) acquired thrombotic thrombocytopenic purpura;

[0707] (xii) bullous pemphigoid;

[0708] (xiii) C3 glomerulopathy; (xiv) immune complex-mediated membranoproliferative glomerulonephritis

[0709] (IC-MPGN);

[0710] (xv) cardiac ischemia and reperfusion;

[0711] (xvi) cardiac remodelling;

[0712] (xvii) cardiometabolic disease;

[0713] (xviii) coeliac disease;

[0714] (xix) cold agglutinin disease;

[0715] (xx) a respiratory condition caused by SARs Cov-2;

[0716] (xxi) diabetic kidney disease;

[0717] (xxii) diabetic retinopathy;

[0718] (xxiii) Doyne honeycomb retinal dystrophy, also known as malattia leventinese (DHRD / ML);

[0719] (xxiv) focal segmental glomerulosclerosis (FSGS);

[0720] (xxv) glomerular sclerosis;

[0721] (xxvi) Guillian-Barre syndrome;

[0722] (xxvii) heart failure;

[0723] (xxviii) hemodialysis;

[0724] (xxix) idiopathic thrombocytopenic purpura (ITP);

[0725] (xxx) idiopathic pulmonary fibrosis;

[0726] (xxxi) IgA nephropathy;

[0727] (xxxii) ischemic stroke;

[0728] (xxxiii) systemic lupus erythematosus;

[0729] (xxxiv) lupus nephritis;

[0730] (xxxv) lupus cerebritis;

[0731] (xxxvi) malignant nephrosclerosis;

[0732] (xxxvii) multiple sclerosis;

[0733] (xxxviii) myasthenia gravis;

[0734] (xxxix) neuromyelitis optica;

[0735] (xl) non-infectious uveitis;

[0736] (xli) osteoarthritis;

[0737] (xlii) pancreatic cancer;

[0738] (xliii) paroxysmal nocturnal hemoglobinuria (PNH);

[0739] (xliv) photocarcinogenesis;

[0740] (xlv) postinfectious glomerulonephritis;

[0741] (xlvi) pre-eclampsia;

[0742] (xlvii) membranous nephropathy;

[0743] (xlviii) renal allograft; (xlix) retinal detachment;

[0744] (I) retinal ischemia reperfusion;

[0745] (li) rheumatoid arthritis;

[0746] (lii) schizophrenia;

[0747] (liii) a delayed hemolytic transfusion reaction (DHTR) in an individual suffering from sickle cell disease;

[0748] (liv) a vaso-occlusive crisis in sickle cell disease;

[0749] (Iv) spinal cord injury;

[0750] (Ivi) squamous cell carcinoma;

[0751] (Ivii) thrombotic microangiopathy (TMA)-mediated acute kidney injury (AKI);

[0752] (Iviii) transplant-associated thrombotic microangiopathy; or

[0753] (lix) traumatic brain injury.

[0754] In another embodiment, the disease, disorder or condition is a non-cancerous disease, disorder or condition, such as:

[0755] (i) acute kidney injury;

[0756] (ii) age-related macular degeneration;

[0757] (iii) airway hyperresponsiveness with inflammation;

[0758] (iv) Alzheimer's disease;

[0759] (v) amyotrophic lateral sclerosis;

[0760] (vi) ANCA vasculitis;

[0761] (vii) antiphospholipid syndrome;

[0762] (viii) aortic stenosis;

[0763] (ix) atypical hemolytic uremic syndrome;

[0764] (x) acquired partial lipodystrophy;

[0765] (xi) acquired thrombotic thrombocytopenic purpura;

[0766] (xii) bullous pemphigoid;

[0767] (xiii) C3 glomerulopathy;

[0768] (xiv) immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN);

[0769] (xv) cardiac ischemia and reperfusion;

[0770] (xvi) cardiac remodelling;

[0771] (xvii) cardiometabolic disease;

[0772] (xviii) coeliac disease;

[0773] (xix) cold agglutinin disease;

[0774] (xx) a respiratory condition caused by SARs Cov-2;

[0775] (xxi) diabetic kidney disease; (xxii) diabetic retinopathy;

[0776] (xxiii) Doyne honeycomb retinal dystrophy, also known as malattia leventinese (DHRD / ML);

[0777] (xxiv) focal segmental glomerulosclerosis (FSGS);

[0778] (xxv) glomerular sclerosis;

[0779] (xxvi) Guillian-Barre syndrome;

[0780] (xxvii) heart failure;

[0781] (xxviii) hemodialysis;

[0782] (xxix) idiopathic thrombocytopenic purpura (ITP);

[0783] (xxx) idiopathic pulmonary fibrosis;

[0784] (xxxi) IgA nephropathy;

[0785] (xxxii) ischemic stroke;

[0786] (xxxiii) systemic lupus erythematosus;

[0787] (xxxiv) lupus nephritis;

[0788] (xxxv) lupus cerebritis;

[0789] (xxxvi) multiple sclerosis;

[0790] (xxxvii) myasthenia gravis;

[0791] (xxxviii) neuromyelitis optica;

[0792] (xxxix) non-infectious uveitis;

[0793] (xl) osteoarthritis;

[0794] (xli) paroxysmal nocturnal hemoglobinuria (PNH);

[0795] (xlii) postinfectious glomerulonephritis;

[0796] (xliii) pre-eclampsia;

[0797] (xliv) membranous nephropathy;

[0798] (xlv) renal allograft;

[0799] (xlvi) retinal detachment;

[0800] (xlvii) retinal ischemia reperfusion;

[0801] (xlviii) rheumatoid arthritis;

[0802] (xlix) schizophrenia;

[0803] (I) a delayed hemolytic transfusion reaction (DHTR) in an individual suffering from sickle cell disease;

[0804] (li) a vaso-occlusive crisis in sickle cell disease;

[0805] (lii) spinal cord injury;

[0806] (liii) thrombotic microangiopathy (TMA)-mediated acute kidney injury (AKI);

[0807] (liv) transplant-associated thrombotic microangiopathy; or

[0808] (Iv) traumatic brain injury. Examples of diseases, disorders or conditions which may be responsive to Factor B inhibition and which may be treated or prevented in accordance with sixth, seventh, eighth, ninth, tenth or eleventh aspect of the present invention are listed above.

[0809] Moreover, some of the diseases, disorders or conditions mentioned above arise due to mutations in (i) Complement C3, (ii) Factor B, (iii) a direct or indirect regulator of Factor B, or (iv) an enzyme that directly or indirectly causes the production or activation of Factor B. Such mutations may give rise to an increase in alternative pathway activity which may be effectively treated by Factor B inhibition. As a result, such diseases, disorders or conditions may be particularly responsive to Factor B inhibition and may be particularly suitable for treatment or prevention in accordance with the sixth, seventh, eighth, ninth, tenth or eleventh aspect of the present invention. Examples of such diseases, disorders or conditions include atypical hemolytic uremic syndrome (aHUS), and age-related macular degeneration (AMD).

[0810] A twelfth aspect of the invention provides a method of inhibiting Factor B, the method comprising the use of a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect of the invention, or a pharmaceutical composition of the fifth aspect of the invention, to inhibit Factor B.

[0811] In one embodiment of the twelfth aspect of the present invention, the method is performed ex vivo or in vitro, for example in order to analyse the effect on cells of Factor B inhibition. Typically, where the method is performed ex vivo or in vitro, the method is not a method of treatment of the human or animal body.

[0812] In another embodiment of the twelfth aspect of the present invention, the method is performed in vivo. For example, the method may comprise the step of administering an effective amount of a compound of the first, second or third aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect, or a pharmaceutical composition of the fifth aspect, to thereby inhibit Factor B. Typically, the administration is to a subject in need thereof.

[0813] Alternately, the method of the twelfth aspect of the invention may be a method of inhibiting Factor B in a non-human animal subject, the method comprising the steps of administering the compound, salt, solvate, prodrug or pharmaceutical composition to the non-human animal subject and optionally subsequently mutilating or sacrificing the non-human animal subject. Typically, such a method further comprises the step of analysing one or more tissue or fluid samples from the optionally mutilated or sacrificed non-human animal subject.

[0814] A thirteen aspect of the invention provides a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect of the invention, or a pharmaceutical composition of the fifth aspect, for use in the inhibition of Factor B. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to a subject.

[0815] A fourteenth aspect of the invention provides the use of a compound of the first, second or third aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the fourth aspect of the invention, in the manufacture of a medicament for the inhibition of Factor B. Typically, the inhibition comprises the administration of the compound, salt, solvate, prodrug or medicament to a subject.

[0816] Unless stated otherwise, in any of the sixth to fourteenth aspects of the invention, the subject may be any human or other animal. Typically, the subject is a mammal, more typically a human or a domesticated mammal such as a cow, pig, lamb, sheep, goat, horse, cat, dog, rabbit, mouse etc. Most typically, the subject is a human.

[0817] Any of the medicaments employed in the present invention can be administered by oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intraarticular, intracranial and epidural), airway (aerosol), rectal, vaginal, ocular or topical (including transdermal, buccal, mucosal, sublingual and topical ocular) administration.

[0818] Typically, the mode of administration selected is that most appropriate to the disorder, disease or condition to be treated or prevented.

[0819] For oral administration, the compounds, salts, solvates or prodrugs of the present invention will generally be provided in the form of tablets, capsules, hard or soft gelatine capsules, caplets, troches or lozenges, as a powder or granules, or as an aqueous solution, suspension or dispersion. Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose. Corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatine. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material, such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Tablets may also be effervescent and / or dissolving tablets.

[0820] Capsules for oral use include hard gelatine capsules in which the active ingredient is mixed with a solid diluent, and soft gelatine capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

[0821] Powders or granules for oral use may be provided in sachets or tubs. Aqueous solutions, suspensions or dispersions may be prepared by the addition of water to powders, granules or tablets.

[0822] Any form suitable for oral administration may optionally include sweetening agents such as sugar, flavouring agents, colouring agents and / or preservatives.

[0823] Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

[0824] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0825] For parenteral use, the compounds, salts, solvates or prodrugs of the present invention will generally be provided in a sterile aqueous solution or suspension, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride or glucose. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate. The compounds of the invention may also be presented as liposome formulations.

[0826] For ocular administration, the compounds, salts, solvates or prodrugs of the invention will generally be provided in a form suitable for topical administration, e.g. as eye drops. Suitable forms may include ophthalmic solutions, gel-forming solutions, sterile powders for reconstitution, ophthalmic suspensions, ophthalmic ointments, ophthalmic emulsions, ophthalmic gels and ocular inserts. Alternatively, the compounds, salts, solvates or prodrugs of the invention may be provided in a form suitable for other types of ocular administration, for example as intraocular preparations (including as irrigating solutions, as intraocular, intravitreal or juxtascleral injection formulations, or as intravitreal implants), as packs or corneal shields, as intracameral, subconjunctival or retrobulbar injection formulations, or as iontophoresis formulations.

[0827] For transdermal and other topical administration, the compounds, salts, solvates or prodrugs of the invention will generally be provided in the form of ointments, cataplasms (poultices), pastes, powders, dressings, creams, plasters or patches.

[0828] Suitable suspensions and solutions can be used in inhalers for airway (aerosol) administration.

[0829] The dose of the compounds, salts, solvates or prodrugs of the present invention will, of course, vary with the disease, disorder or condition to be treated or prevented. In general, a suitable dose will be in the range of 0.01 to 500 mg per kilogram body weight of the recipient per day. The desired dose may be presented at an appropriate interval such as once every other day, once a day, twice a day, three times a day or four times a day. The desired dose may be administered in unit dosage form, for example, containing 1 mg to 50 g of active ingredient per unit dosage form.

[0830] A fifteenth aspect of the invention provides a method of synthesising a compound according to the first aspect of the invention, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, the method comprising the steps of:

[0831] (i) reacting a compound of Formula (SM-1) with a compound of Formula R10-L-COOH to produce an intermediate of Formula (It-1) : and

[0832] (ii) deprotecting the intermediate of Formula (It- 1) to produce a compound of Formula (I), or a pharmaceutically acceptable salt and / or solvate thereof: Formula (lt-1) Formula (I) wherein :

[0833] Rpis a nitrogen protecting group; and

[0834] R1, R2, Q3, R4to R10and L are as defined in accordance with the first aspect of the invention.

[0835] In one embodiment of the fifteenth aspect of the invention, Q3is C-R3.

[0836] In another embodiment of the fifteenth aspect of the invention, Q3is N. A sixteenth aspect of the invention provides a method of synthesising a compound according to the second aspect of the invention, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, the method comprising the steps of: (i) reacting a compound of Formula (SM-2) with a compound of Formula R10-L-COOH to produce an intermediate of Formula (It-2) : and

[0837] (ii) deprotecting the intermediate of Formula (It-2) to produce a compound of

[0838] Formula (II), or a pharmaceutically acceptable salt and / or solvate thereof: wherein :

[0839] Rpis a nitrogen protecting group; and

[0840] R1, R4to R10, R14to R17, and L are as defined in accordance with the second aspect of the invention. As stated in accordance with the fifteenth and sixteenth aspects of the invention, Rpis a nitrogen protecting group. Suitable nitrogen protecting groups may be identified by reference to e.g. Wuts, "Greene's Protective Groups in Organic Synthesis", 5thEd., 2014.

[0841] In one embodiment of the fifteenth or sixteenth aspect of the invention, Rpis a nitrogen protecting group that is stable under basic conditions. Typically, Rpis also stable under weak nucleophilic conditions. For example, Rpmay be selected from the group consisting of benzyloxycarbonyl (CBz), 4-methoxy-benzyloxycarbonyl, benzyl, t-butoxycarbonyl (Boc), 2-(4-biphenylyl)-isopropoxycarbonyl (Bpoc), triphenylmethyl (Trt) and 2,2,2-trichloroethoxycarbonyl (Troc) protecting groups. Alternatively, Rpmay be a sulphonyl group, such as a such as a toluenesulphonyl (tosyl or -Ts), methanesulfonyl (mesyl or -Ms), or trifluoromethanesulfonyl (triflyl or -Tf) group.

[0842] In one embodiment of the fifteenth or sixteenth aspect of the invention, Rpis a t- butoxycarbonyl (Boc) group.

[0843] In another embodiment of the fifteenth or sixteenth aspect of the invention, Rpis a toluenesulphonyl (tosyl or -Ts) group.

[0844] Typically, the reaction of step (i) of the fifteenth or sixteenth aspect of the invention occurs in the presence of a peptide coupling reagent. In one embodiment, the peptide coupling reagent is a carbodiimide such as / V, / V'-dicyclohexylcarbodiimide (DCCI), / V, / V'-diisopropylcarbodiimide (DIC) or l-ethyl-3-(3-dimethylaminopropyl)- carbodiimide (EDCI). Typically, where the peptide coupling reagent is a carbodiimide, the reaction occurs in the presence of an N-hydroxylated heteroaryl compound, more typically a 1-hydroxytriazole such as 1-hydroxybenzotriazole (HOBt), l-hydroxy-7-azabenzotriazole (HOAt) or ethyl l-hydroxy-lH-l,2,3-triazole- 4-carboxylate (HOCt).

[0845] In an alternate embodiment, the peptide coupling reagent is a uronium or guanidinium salt such as hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), hexafluorophosphate benzotriazole tetramethyl uronium (HBTU), O-(lH-6-chlorobenzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HCTU), 2-(lH-Benzotriazole-l-yl)-l,l,3,3-tetramethylaminium tetrafluoroborate (TBTU) or tetramethylfluoroformamidinium hexafluoro- phosphate (TFFH). Typically, the peptide coupling reagent is hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU).

[0846] Typically, the reaction of step (i) of the fifteenth or sixteenth aspect of the invention occurs in the presence of a base. Typically the base is a tertiary amine base such as TEA, DIPEA or tributylamine. Most typically, the base is DIPEA.

[0847] Typically, the reaction of step (i) of the fifteenth or sixteenth aspect of the invention occurs in the presence of a dipolar aprotic solvent, such as dimethyl sulfoxide, N,N- dimethylformamide, N,N'-dimethylpropyleneurea, tetra hydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, or N-methyl pyrrolidone. More typically, the solvent is N,N-dimethylformamide.

[0848] The deprotection of step (ii) of the fifteenth or sixteenth aspect of the invention may occur simultaneously with the reaction of step (i), e.g. via a 'one-pot' method, or may occur sequentially. As will be appreciated, the deprotection conditions will be appropriate to the type of nitrogen protecting group Rpused. For example, where Rpis a t-butoxycarbonyl (Boc) group, deprotection may be effected by treatment of the intermediate of Formula (It- 1) or (It-2) with :

[0849] (i) TMS-OTf and 2,6-lutidine, or TMS-OTf and TEA, in a dipolar aprotic solvent, such as dichloromethane; or

[0850] (ii) a lewis acid, such as AICI3, in a dipolar aprotic solvent, such as dichloromethane; or

[0851] (iii) a polar protic acid such as HCI, HBr or TFA, in a polar protic solvent such as water and / or methanol; or

[0852] (iv) heat treatment in the presence of a fluorinated alcohol such as trifluoroethanol or hexafluoroisopropanol.

[0853] Similarly, where Rpis a toluenesulphonyl (tosyl or -Ts) group, deprotection may be effected by treatment of the intermediate of Formula (It- 1) or (It-2) with TBAF in a dipolar aprotic solvent, such as tetra hydro furan.

[0854] Optionally, the method of the fifteenth aspect of the invention further comprises the step of (iii) converting the compound of Formula (I) into a different compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. Alternately or in addition, the method of the fifteenth aspect of the invention may further comprise the step (ia) of converting the compound of Formula (It- 1) into a different compound of Formula (It-1), or a pharmaceutically acceptable salt and / or solvate thereof, prior to the deprotection step (ii).

[0855] Optionally, the method of the sixteenth aspect of the invention further comprises the step of (iii) converting the compound of Formula (II) into a different compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof. Alternately or in addition, the method of the sixteenth aspect of the invention may further comprise the step (ia) of converting the compound of Formula (It-2) into a different compound of Formula (It-2), or a pharmaceutically acceptable salt and / or solvate thereof, prior to the deprotection step (ii).

[0856] A seventeenth aspect of the invention provides a method of synthesising a compound according to the second aspect of the invention, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, the method comprising the step of:

[0857] (i) reducing a compound of Formula (P-1) to compound of Formula (P-2), or a pharmaceutically acceptable salt and / or solvate thereof: wherein :

[0858] Rxis selected from hydrogen or Rp;

[0859] Rpis a nitrogen protecting group; and

[0860] R2to R10, L, and R14to R17are as defined in accordance with the first and / or second aspect of the invention. As will be understood, where Rxis hydrogen, the compound of Formula (P-1) is a compound of Formula (la) of the first aspect of the invention, and the compound of Formula (P-2) is a compound of Formula (II) of the second aspect of the invention.

[0861] Typically in accordance with the seventeenth aspect of the invention, at least one of R14and R15is hydrogen, and at least one of R16and R17is hydrogen.

[0862] In one embodiment of the seventeenth aspect of the invention, Rxis Rp. Typically, Rpis a nitrogen protecting group that is stable under basic conditions. Typically, Rpis also stable under weak nucleophilic conditions. For example, Rpmay be selected from the group consisting of benzyloxycarbonyl (CBz), 4-methoxy- benzyloxycarbonyl, benzyl, t-butoxycarbonyl (Boc), 2-(4-biphenylyl)- isopropoxycarbonyl (Bpoc), triphenylmethyl (Trt) and 2,2,2-trichloroethoxycarbonyl (Troc) protecting groups.

[0863] In one embodiment of the seventeenth aspect of the invention, Rpis a t- butoxycarbonyl (Boc) group.

[0864] In one embodiment of the seventeenth aspect of the invention, the reduction of step (i) is performed using a hydride donor (such as NaBHsCN, BH3 or EtsSiH), optionally in the presence of an acid (such as acetic acid or trifluoroacetic acid).

[0865] Typically, the reduction of step (i) of the seventeenth aspect of the invention occurs in the presence of a dipolar aprotic solvent, such as dimethyl sulfoxide, N,N- dimethylformamide, / V, / Vz-dimethylpropyleneurea, tetra hydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, or / V-methyl pyrrolidone.

[0866] Where Rxis a nitrogen protecting group, optionally the method of the seventeenth aspect of the invention further comprises the step of (ii) deprotecting the compound of Formula (P-2) to produce a compound of Formula (II), or a pharmaceutically acceptable salt and / or solvate thereof.

[0867] The deprotection of step (ii) may occur simultaneously with the reaction of step (i), e.g. via a 'one-pot' method, or may occur sequentially. As will be appreciated, the deprotection conditions will be appropriate to the type of nitrogen protecting group Rpused. For example, where Rpis a t-butoxycarbonyl (Boc) group, deprotection may be effected by treatment of the protected compound of Formula (P-2) with TMS-OTf and 2,6-lutidine in a dipolar aprotic solvent, such as dichloromethane.

[0868] Optionally, the method of the seventeenth aspect of the invention further comprises the step of (iii) converting the compound of Formula (II) into a different compound of Formula (II), or a pharmaceutically a...

Claims

Claims1. A compound of Formula (I):Formula (I) or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof; wherein :R1is hydrogen;R2is selected from hydrogen or a halo, -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety;Q3is selected from N or C-R3;R3is selected from hydrogen or a halo, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety;R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety;R5is selected from hydrogen or a halo group;R6is selected from a halo, -R60or -OR60group, wherein R60is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group;R7and R8are each independently selected from hydrogen or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton; or R3and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms eachindependently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom;R9is hydrogen;L is selected from a bond, -0-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; andR10is a 3- to 12-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

2. A compound as claimed in claim 1, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R2is selected from hydrogen or a fluoro, chloro, bromo, methyl or fluoromethyl group.

3. A compound as claimed in claim 1 or claim 2, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein Q3is C-R3.

4. A compound as claimed in claim 3, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R3is selected from hydrogen or a fluoro, chloro, bromo, -R30, -CH2R30, -CN, -CHO, -COR30, -CO2H or -CO2R30group, wherein R30is selected from a C1-C4 alkyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl or C3-C4 fluorocycloalkyl group.

5. A compound as claimed in claim 1 or claim 2, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein Q3is N.

6. A compound as claimed in claim 5, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein :(i) L is selected from -O-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; and / or(ii) R10is a 3- to 12-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -SH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety; and / or(iii) the cyclic group of R10is substituted with at least one -CN, fluoromethyl or fluoromethoxy group; and / or(iv) R10is a 5- or 6-membered heteroaryl group, wherein the heteroaryl group may optionally be substituted with one or more substituents each independently selected from a halo, -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or moreheteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

7. A compound of Formula (II):or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof; wherein :R1is hydrogen;R4is selected from hydrogen or a halo, -OH, -NH2, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety;R5is selected from hydrogen or a halo group;R6is selected from a halo, -R60or -OR60group, wherein R60is selected from a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group;R7and R8are each independently selected from hydrogen or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups,wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of any hydrocarbyl group of R7or R8that is directly attached to the reminder of the molecule is a carbon atom; or R7and R8together with the carbon atom to which they are attached form a 3- to 10-membered cyclic group, such that each ring atom of the cyclic group that is directly attached to the carbon atom to which R7and R8are attached is a ring carbon atom, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -NH2 or a C1-C4 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include a cyclic group, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, and wherein the hydrocarbyl group may optionally include one or two heteroatoms each independently selected from N and O in its carbon skeleton;R9is hydrogen;R14is selected from hydrogen or a C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl or C3-C4 fluorocycloalkyl group; andR15is selected from hydrogen or a -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety; or R14and R15together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted;R16is selected from hydrogen or a fluoro, -SO2NH2, or a Ci-Cs saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight- chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups,wherein the hydrocarbyl group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety;R17is selected from hydrogen or a fluoro, C1-C4 alkyl, cyclopropylmethyl, C3-C4 cycloalkyl, C1-C4 fluoroalkyl, fluorocyclopropylmethyl, or C3-C4 fluorocycloalkyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 6-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a fluoro, -OH, oxo (=0), methyl or ethyl group, wherein any methyl or ethyl group may optionally be fluoro substituted; or R17and R7, or R4and R7, together form a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, provided that the atom of the hydrocarbylene group that is directly attached to the carbon atom to which R8is attached is a carbon atom;L is selected from a bond, -0-, -S-, -NH-, or a Ci-Ce saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbylene group may optionally be substituted with one or more halo groups, wherein the hydrocarbylene group may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, wherein any -S- moiety that is not directly attached to the carbon atom of the carbonyl group of -NR9-CO- may optionally be substituted with one or two groups each independently selected from oxo (=0) and =NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety, and wherein the hydrocarbylene group has a chain length of from 1 to 3 atoms; andR10is a 3- to 12-membered cyclic group, wherein the cyclic group may optionally be substituted with one or more substituents each independently selected from a halo, oxo (=0), -OH, -SH, -NH2, -SO2NH2, or a C1-C12 saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include one or more cyclic groups, wherein the hydrocarbyl group may optionally be substituted with one or more halo groups, wherein the hydrocarbylgroup may optionally include one or more heteroatoms each independently selected from N, O and S in its carbon skeleton, and wherein any -S- moiety may optionally be substituted with one or two groups each independently selected from oxo ( = 0) and = NH to form a -SO-, -SO2-, -S(=NH)- or -SO( = NH)- moiety.

8. A compound as claimed in claim 7, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein each R14and R15is independently selected from hydrogen or a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group, or R14and R15together with the carbon atom to which they are attached may form a cyclopropyl or a cyclobutyl group, wherein the cyclopropyl or cyclobutyl group may optionally be substituted with one or more fluoro groups.

9. A compound as claimed in claim 7 or claim 8, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein :R16is selected from hydrogen or a fluoro, -R160, -CN, -CHO, -COR160, -CO2H or -CO2R160group, wherein R160is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group; andR17is selected from hydrogen or a fluoro, C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group; or R16and R17together with the carbon atom to which they are attached form a 3- to 5-membered saturated monocyclic group wherein the saturated monocyclic group may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from oxo (=0) or a methyl or fluoromethyl group.

10. A compound as claimed in any one of claims 1 to 9, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein :R4is selected from a fluoro, chloro, bromo, -OH, -OR41, -N(R42)2, -SO2-R41, -SO2-N(R42)2, -L4-OH, -L4-OR41, -L4-N(R42)2, -L4-SO2-R41, -L4-SO2-N(R42)2, -O-L4-OH, -O-L4-OR41, -O-L4-N(R42)2, -O-L4-SO2-R41, -O-L4-SO2-N(R42)2, -NR43-L4-OH, -NR43-L4-OR41, -NR43-L4-N(R42)2, -NR43-L4-SO2-R41, -NR43-L4-SO2-N(R42)2, -SO2-L4-OH, -SO2-L4-OR41, -SO2-L4-N(R42)2, -R44, -R45or -L4-R45group;R41is selected from a -R44or -R45group; each R42is independently selected from hydrogen or a -R44or -R45group, or any two R42may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;L4is a straight-chained alkylene group, wherein the straight-chained alkylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L4has a chain length of from 1 to 4 atoms, and wherein L4may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL4; each RL4is independently selected from a fluoro, methyl or fluoromethyl group; or any RL4and R41, or any RL4and any R42, may together with the atoms to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6-membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;R43is selected from hydrogen or a -R44group; each R44is independently selected from a C1-C4 alkyl, C3-C6 cycloalkyl or C4-C6 cycloalkylalkyl group, wherein the C1-C4 alkyl, C3-C6 cycloalkyl or C4-C6 cycloalkylalkyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; and each R45is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group may optionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe?, wherein any methyl group of R45may optionally be fluoro substituted; provided that R4, including any optional substituents, contains no more than 8 carbon atoms.

11. A compound as claimed in any one of claims 1 to 10, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R5is selected from hydrogen or a fluoro, chloro or bromo group.

12. A compound as claimed in any one of claims 1 to 11, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein :R6is selected from a -R60or -OR60group; andR60is selected from a C1-C3 alkyl, cyclopropyl, C1-C3 fluoroalkyl or fluorocyclopropyl group.

13. A compound as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein :R7is selected from hydrogen or a -CN, -COOH, -COOR71, -CO-N(R72)2, -L7-COOH, -L7-COOR71, -L7-CO-N(R72)2, -L7-OH, -L7-OR71, -L7-N(R72)2, -R73, -R74or -L7-R74group, provided that R7, including any optional substituents, contains no more than 8 carbon atoms, and that the atom of R7that is directly attached to the reminder of the molecule is a carbon or hydrogen atom;R71is selected from a -R73or -R74group; each R72is independently selected from hydrogen or a -R73or -R74group, or any two R72may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated monocyclic heterocyclic group, wherein the 3- to 6- membered saturated monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups;L7is a straight-chained alkylene or alkenylene group, wherein the straight- chained alkylene or alkenylene group optionally includes one or two heteroatoms each independently selected from O and N in its carbon skeleton, wherein L7has a chain length of from 1 to 4 atoms, and wherein L7may optionally be substituted with one or two oxo (=0) groups and / or with one or more groups RL7; each RL7is independently selected from a fluoro, methyl or fluoromethyl group; or any two RL7may, together with the atom or atoms to which they are attached, form a 3- to 6-membered monocyclic group, wherein the 3- to 6-membered monocyclic group is saturated or monounsaturated, and wherein the 3- to 6- membered monocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; or any RL7and R71, or any RL7and any R72, may together with the atoms of the -L7-COOR71, -L7-CO-N(R72)2, -L7-OR71or -L7-N(R72)2group to which they are attached, form a 3- to 6-membered monocyclic heterocyclic group, wherein the 3- to 6- membered monocyclic heterocyclic group is saturated or monounsaturated, and wherein the 3- to 6-membered monocyclic heterocyclic group may optionally be substituted with one or two oxo (=0) groups and / or with one or more fluoro, methyl and / or fluoromethyl groups; each R73is independently selected from a C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4-C6 cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group, wherein the C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C4-C6 cycloalkylalkyl, Cs-Ce cycloalkenyl, Cs-Ce cycloalkenylalkyl or Cs-Ce cycloalkylalkenyl group may optionally be substituted with one or more fluoro groups and / or one or two oxo (=0) groups; each R74is independently selected from a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group mayoptionally be substituted with one or more groups each independently selected from fluoro, chloro and bromo, and / or with one or two groups each independently selected from methyl (Me), -CN, -OH, -OMe, -NH2, -NHMe, and -NMe?, wherein any methyl group of R74may optionally be fluoro substituted; andR8is selected from a hydrogen or a methyl or fluoromethyl group; or R7and R8together form a group -L78-, wherein -L78- is selected from a -CH2-CH2-, -CH2-CH2-CH2-, -CH2-NH-CH2-, -CH2-O-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-NH-CH2-, -CH2-CH2-O-CH2-, -CH2-NH-CH2-CH2- or -CH2-O-CH2-CH2- group, wherein -L78- may optionally be substituted with one or more fluoro groups and / or one or two substituents each independently selected from an oxo ( = 0), -CN, methyl (Me), -OH, -OMe, -NH2, -NHMe or -NMe2 group, and wherein any methyl group of a -L78- substituent may optionally be fluoro substituted.

14. A compound as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein L is selected from a bond, -NH-, or a -C(RL)2- group, wherein each RLis independently selected from hydrogen or a fluoro, methyl or fluoromethyl group, or the two RLmay together with the carbon atom to which they are attached form a cyclopropyl group, wherein the cyclopropyl group may optionally be fluoro substituted.

15. A compound as claimed in any one of claims 1 to 14, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, wherein R10is a 5- to 10- membered aryl or heteroaryl group, wherein the aryl or the heteroaryl group may optionally be substituted with one or more fluoro, chloro and / or bromo groups, and / or with one or two non-halo substituents each independently selected from an -OH, -SH, -NH2, -CN, or a Ci-Cs saturated hydrocarbyl group, wherein the saturated hydrocarbyl group may be straight-chained or branched, or be or include a single cyclic group, wherein the saturated hydrocarbyl group may optionally be substituted with one or more fluoro groups and / or with one or two oxo (=0) groups, and wherein the saturated hydrocarbyl group may optionally include one, two or three heteroatoms each independently selected from N, O and S in its carbon skeleton.

16. A compound selected from the group consisting of:or a pharmaceutically acceptable salt and / or solvate and / or prodrug of the selected compound.

17. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 16, and a pharmaceutically acceptable excipient.

18. A compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 16, or a pharmaceutical composition as claimed in claim 17, for use in medicine.

19. A compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 16, or a pharmaceutical composition as claimed in claim 17, for use in the treatment or prevention of a disease, disorder or condition, wherein the disease, disorder or condition is responsive to Factor B inhibition.

20. A compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, or a pharmaceutical composition, as claimed in claim 18 or claim 19, for use in the treatment or prevention of a disease, disorder or condition, wherein the disease, disorder or condition is non-cancerous.

21. A compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, or a pharmaceutical composition, as claimed in any one of claims 18 to 20, for use in the treatment or prevention of a disease, disorder or condition, wherein the disease, disorder or condition is selected from :(i) an ocular disease, disorder or condition;(ii) a haematological disease, disorder or condition;(iii) a renal disease, disorder or condition;(iv) a respiratory disease, disorder or condition;(v) a central nervous system disease, disorder or condition;(vi) a cardiovascular disease, disorder or condition;(vii) a reproductive disease, disorder or condition;(viii) a metabolic disease, disorder or condition;(ix) a cancer;(x) an auto-immune disease, disorder or condition;(xi) a musculoskeletal disease, disorder or condition;(xii) antiphospholipid syndrome;(xiii) a skin disease, disorder or condition;(xiv) hemodialysis; or(xv) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in Factor B.

22. A compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, or a pharmaceutical composition, as claimed in any one of claims 18 to 20, for use in the treatment or prevention of a disease, disorder or condition, wherein the disease, disorder or condition is selected from :(i) acute kidney injury;(ii) age-related macular degeneration;(iii) airway hyperresponsiveness with inflammation;(iv) Alzheimer's disease;(v) amyotrophic lateral sclerosis;(vi) ANCA vasculitis;(vii) antiphospholipid syndrome;(viii) aortic stenosis;(ix) atypical hemolytic uremic syndrome;(x) acquired partial lipodystrophy;(xi) acquired thrombotic thrombocytopenic purpura;(xii) bullous pemphigoid;(xiii) C3 glomerulopathy;(xiv) immune complex-mediated membranoproliferative glomerulonephritis (IC- MPGN);(xv) cardiac ischemia and reperfusion;(xvi) cardiac remodelling;(xvii) cardiometabolic disease;(xviii) coeliac disease;(xix) cold agglutinin disease;(xx) a respiratory condition caused by SARs Cov-2;(xxi) diabetic kidney disease;(xxii) diabetic retinopathy;(xxiii) Doyne honeycomb retinal dystrophy, also known as malattia leventinese (DHRD / ML);(xxiv) focal segmental glomerulosclerosis (FSGS);(xxv) glomerular sclerosis;(xxvi) Guillian-Barre syndrome;(xxvii) heart failure;(xxviii) hemodialysis;(xxix) idiopathic thrombocytopenic purpura (ITP);(xxx) idiopathic pulmonary fibrosis;(xxxi) IgA nephropathy;(xxxii) ischemic stroke;(xxxiii) systemic lupus erythematosus;(xxxiv) lupus nephritis;(xxxv) lupus cerebritis;(xxxvi) malignant nephrosclerosis;(xxxvii) multiple sclerosis;(xxxviii) myasthenia gravis;(xxxix) neuromyelitis optica;(xl) non-infectious uveitis;(xli) osteoarthritis;(xlii) pancreatic cancer;(xliii) paroxysmal nocturnal hemoglobinuria (PNH);(xliv) photocarcinogenesis;(xlv) postinfectious glomerulonephritis;(xlvi) pre-eclampsia;(xlvii) membranous nephropathy;(xlviii) renal allograft;(xlix) retinal detachment;(I) retinal ischemia reperfusion;(li) rheumatoid arthritis;(lii) schizophrenia;(liii) a delayed hemolytic transfusion reaction (DHTR) in an individual suffering from sickle cell disease;(liv) a vaso-occlusive crisis in sickle cell disease;(Iv) spinal cord injury;(Ivi) squamous cell carcinoma;(Ivii) thrombotic microangiopathy (TMA)-mediated acute kidney injury (AKI); (Iviii) transplant-associated thrombotic microangiopathy; or(lix) traumatic brain injury.

23. A method of inhibiting Factor B, the method comprising the use of a compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in any one of claims 1 to 16, or a pharmaceutical composition as claimed in claim 17, to inhibit Factor B.

24. A method of synthesising a compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in claim 1, the method comprising the steps of:(i) reacting a compound of Formula (SM-1) with a compound of FormulaR10-L-COOH to produce an intermediate of Formula (It-1) :and(ii) deprotecting the intermediate of Formula (It-1) to produce a compound of Formula (I), or a pharmaceutically acceptable salt and / or solvate thereof:wherein :Rpis a nitrogen protecting group; andR1, R2, Q3, R4to R10and L are as defined in accordance with claim 1.

25. A method of synthesising a compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in claim 7, the method comprising the steps of:(i) reacting a compound of Formula (SM-2) with a compound of Formula R10-L-COOH to produce an intermediate of Formula (It-2) :and(ii) deprotecting the intermediate of Formula (It-2) to produce a compound ofFormula (II), or a pharmaceutically acceptable salt and / or solvate thereof:wherein :Rpis a nitrogen protecting group; andR1, R4to R10, R14to R17, and L are as defined in accordance claim 7.

26. A method of synthesising a compound, or a pharmaceutically acceptable salt and / or solvate and / or prodrug thereof, as claimed in claim 7, the method comprising the step of:(i) reducing a compound of Formula (P-1) to compound of Formula (P-2), or a pharmaceutically acceptable salt and / or solvate thereof:wherein :Rxis selected from hydrogen or Rp;Rpis a nitrogen protecting group;R4to R10, L, and R14to R17are as defined in accordance with claim 7; andR2and R3are as defined in accordance with claim 1.

Images